

RODENT STROKE MODEL GUIDELINES FOR PRECLINICAL STROKE TRIALS (1ST EDITION)

Shimin Liu, MD, PhD^{1*}; Gehua Zhen MD, PhD²; Bruno P. Meloni, PhD³; Kym Campbell, BVMS³; H Richard Winn, MD⁴

1 Department of Neurology, Stroke Center, 4 Department of Neurosurgery, Mount Sinai School of Medicine of NYU, New York, NY, USA

2 Department of Anesthesiology, Johns Hopkins School of Medicine, Baltimore, MD, USA

3 Centre for Neuromuscular and Neurological Disorders, University of Western Australia, Australian Neuromuscular Research Institute, Department of Neurosurgery, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.

ABSTRACT

Translational stroke research is a challenging task that needs long term team work of the stroke research community. Highly reproducible stroke models with excellent outcome consistence are essential for obtaining useful data from preclinical stroke trials as well as for improving inter-lab comparability. However, our review of literature shows that the infarct variation coefficient of commonly performed stroke models ranges from 5% to 200%. An overall improvement of the commonly used stroke models will further improve the quality for experimental stroke research as well as inter-lab comparability. Many factors play a significant role in causing outcome variation; however, they have not yet been adequately addressed in the Stroke Therapy Academic Industry Roundtable (STAIR) recommendations and the Good Laboratory Practice (GLP). These critical factors include selection of anesthetics, maintenance of animal physiological environment, stroke outcome observation, and model specific factors that affect success rate and variation. The authors have reviewed these major factors that have been reported to influence stroke model outcome, herewith, provide the first edition of stroke model guidelines so to initiate active discussion on this topic. We hope to reach a general agreement among stroke researchers in the near future with its successive updated versions.

Keywords: Acute stroke; animal model; neuroprotection; middle cerebral artery occlusion; guidelines; consistency

* Correspondence should be sent to:

Shimin Liu, M.D., Ph.D.
Department of Neurology, Mount Sinai School of Medicine NYU.
1468 Madison Avenue, New York, NY 10029
E-mail: shimin.liu@mssm.edu
Phone: (212) 241-2252
Fax: (212) 241-6971

Copyright © 2009 SFES 1939-067X/09

TABLE OF CONTENTS

ABSTRACT	- 2 -
ABBREVIATION	- 4 -
DEFINITION	- 5 -
1. INTRODUCTION	- 5 -
2. GENERAL GUIDANCE FOR A PRECLINICAL STROKE TRIAL	- 5 -
3. REVISITING THE STAIR CRITERIA	- 5 -
4. STROKE MODEL SELECTION	- 6 -
TABLE 1. SUMMARY OF STROKE MODEL SELECTION	- 7 -
TABLE 2. COMPARISON OF THE INTRALUMINAL MODEL AND THE TAMURA MODEL	- 8 -
5. THE INTRALUMINAL MODEL	- 9 -
A. THE SELECTION OF MCAO OCCLUDERS	- 9 -
B. OPTIMIZATION OF MCAO OCCLUDERS	- 10 -
C. OPTIMIZATION OF SURGICAL PROCEDURES	- 10 -
6. THE TAMURA MODEL	- 11 -
A. ABOUT THE MCA OCCLUDER	- 11 -
B. SURGICAL OPTIMIZATION	- 12 -
C. PURE CORTICAL INFARCTION VERSUS COMBINED INFARCTION	- 12 -
D. INFARCT VOLUME VARIATION AND OPTIMAL ISCHEMIA DURATION	- 12 -
7. INFARCTION VOLUME MEASUREMENT	- 13 -
A. METHODS FOR INFARCTION VISUALIZATION	- 13 -
B. DIRECT VISUALIZATION OF INFARCT ON TTC STAINED FRESH BRAIN SECTIONS	- 14 -
C. DIGITAL METHODS FOR DEFINING THE INFARCTED AREA	- 14 -
D. CALCULATION OF INFARCT VOLUME	- 15 -
E. CALCULATION FORMULAE FOR INFARCTION VOLUME	- 15 -
F. MEASUREMENT OF INFARCTION VOLUME VARIABILITY	- 15 -
8. FUNCTIONAL EVALUATION	- 15 -
A. THE TIMING OF FUNCTIONAL EVALUATION	- 15 -
B. EVALUATION SYSTEMS FOR NEUROLOGICAL FUNCTIONAL DEFICITS	- 16 -
C. ANALYSES FOR NEUROLOGICAL FUNCTIONAL DEFICITS	- 16 -
9. ANESTHETICS	- 16 -

10. TEMPERATURE - 17 -

 A. THE NECESSITY OF MONITORING TEMPERATURE - 17 -

 B. MONITORING BRAIN/CORE TEMPERATURE - 17 -

 C. MAINTAINING BRAIN/CORE TEMPERATURE - 18 -

11. MECHANICAL VENTILATION AND BLOOD GAS/GLUCOSE MONITORING - 18 -

 A. PROPER USE OF MECHANICAL VENTILATION - 18 -

 B. MONITORING GLUCOSE - 19 -

 C. BLOOD SAMPLING FOR BLOOD GAS ANALYSES - 19 -

12. BLOOD PRESSURE - 20 -

13. THE IMPORTANCE OF A PILOT STUDY - 20 -

14. IMPLEMENTATION OF THE PRECLINICAL STROKE TRIAL - 20 -

 A. ADHERE TO “GOOD LABORATORY PRACTICE” - 20 -

 B. USE APPROPRIATE STATISTICAL METHODS FOR DATA ANALYSES - 21 -

15. FACTORS BEYOND SCIENCE - 21 -

 A. THE NEED FOR SOPS FOR STROKE MODELS - 21 -

 B. TECHNICAL CHALLENGES IN STROKE MODELS - 21 -

ACKNOWLEDGEMENT - 21 -

REFERENCES - 21 -

ABBREVIATION

AC:	Alternating Current	LDF:	Laser Doppler Flowmetry
ACA:	Anterior Cerebral Artery	MAP2:	Microtubule-Associated Protein 2
AComA:	Anterior Communicating Arteries	MCA:	Middle Cerebral Artery
AMPA:	Amino-3-Hydroxy-5-Methyl-4-Propionic Acid	MCAO:	Middle Cerebral Artery Occlusion
ATP:	Adenosine Triphosphate	NMDA:	N-Methyl-D-Aspartate
BBB:	Blood-Brain-Barrier	PaCO ₂ :	Partial arterial Carbon Dioxide Pressure
CBF:	Cerebral Blood Flow	PaO ₂ :	Partial arterial Oxygen Pressure
CCA:	Common Carotid Artery	PComA:	Posterior Communicating Arteries
CNS:	Central Nervous System	PID:	Proportional–Integral–Derivative
DC:	Direct Current	PLL:	Poly-L-Lysine
dMCAO:	Distal MCA Occlusion	pMCAO:	Proximal MCA Occlusion
ECA:	External Carotid Artery	pSDM:	Percentage Of Standard Deviation To Mean
GLP:	Good Laboratory Practice	PTA:	Pterygopalatine Artery
GABA:	γ-Aminobutyric-Acid	rCBF:	Regional Cerebral Blood Flow
H&E:	Hematoxylin And Eosin	SAH:	Subarachnoid Hemorrhage
ICA:	Internal Carotid Artery	SD:	Standard Deviation
ISCBFM:	International Society For Cerebral Blood Flow And Metabolism	SEM:	Standard Error Of Mean
		SFES:	Society For Experimental Stroke
		SMG:	Stroke Model Guidelines

SOP:	Standard Operational Procedures
STAIR:	Stroke Therapy Academic Industry Roundtable
tCCAO:	Temporary Common Carotid Artery Occlusion
TTC:	2,3,5-Triphenyltetrazolium Chloride

DEFINITION

pSDM: percent of SD to mean

1. INTRODUCTION

The Stroke Therapy Academic Industry Roundtable (STAIR) was established in order to address the challenges encountered in finding an effective neuroprotective therapy for acute stroke (Fisher *et al.* 2007; Stroke Therapy Academic Industry Roundtable 1999). Besides the STAIR's concern for study design, other issues relating to experimental stroke research, especially animal stroke modeling have been raised (Dirnagl 2006; Savitz 2007; van der Worp *et al.* 2005). This is an important issue, and it is now recommended that any stroke model that aims to achieve scientific and therapeutic value must meet certain requirements. The model must be both highly consistent in inducing injury, performed under conditions to avoid co-founding factors influencing outcomes and widely available to most investigators. With the STAIR guidelines providing an excellent framework for the design of preclinical stroke trials, a detailed guidance for conducting individual experiments using stroke models will further improve model consistency, reliability and inter-lab comparability. A review of literature shows that the infarct variation coefficient of commonly performed stroke models ranges from 5% to 200% (see following paragraphs). Many factors play a significant role in causing outcome variation; however, they are not fully defined in the STAIR guidelines. These critical factors include selection of anesthetics, maintenance of animal physiological environment, stroke outcome observation, and animal species used.

Here we provide the first edition of stroke model guidelines (SMG) so as to initiate an active discussion on this topic, with the ultimate aim of reaching a general agreement among stroke researchers in future up-dated versions. Because rodents are the mostly commonly used animals for preclinical stroke trials, the first version of SMG starts with rodent stroke models. In its successive versions, the contents may expand into stroke models of other species. The SMG starts with a general overview of the design and set-up of a typical preclinical stroke trial, followed by more detailed guidelines on the implementation of each step.

2. GENERAL GUIDANCE FOR A PRECLINICAL STROKE TRIAL

Because investigators have used different units of measurement for the infarction volume and such data have been expressed either in mean \pm SD or mean \pm SEM, we adapted pSDM (percent of SD to mean,) as the coefficient for infarction volume variation for the purpose of increasing comparability between studies. The SEM, when used by many of the original investigators, has been converted to SD for the calculation of the pSDM.

Before starting an experimental preclinical stroke trial the following steps are necessary for ensuring a good quality study. Specific guidance for most steps is provided in subsequent paragraphs.

1. Revisit the latest STAIR criteria for achieving an optimized study design
2. Select the most appropriate stroke model for your study
3. Determine stroke model parameters, such as anticipated infarct size and surgical procedure
4. Determine the use of anesthetics
5. Determine the components of the inhaled gas
6. Determine the necessity and settings of intubation and ventilation
7. Set up monitoring for arterial blood pressure, blood gases, blood glucose
8. Set up temperature monitoring and maintenance
9. Set up regional cerebral blood flow monitoring
10. Determine a protocol for post-operational care
11. Determine the method and timing for infarct volume measurement
12. Determine the appropriate tests and timing for the assessment of functional deficits
13. Do a pilot study and adjust the experimental settings for further optimization
14. Assess the compliance of the trial with "Good Laboratory Practice" standards.

3. REVISITING THE STAIR CRITERIA

GUIDANCE

The design of a preclinical stroke trial should start with a revisiting of the latest version of stroke therapy academic industry roundtable (STAIR) criteria. Receiving some useful suggestions with caution from the STAIR criteria may help with improving the study design to some extent although there are debates on some issues that STAIR addressed.

SUPPORTING DISCUSSION

The STAIR criteria provides some useful recommendations for improving the design of preclinical stroke trials.

To date, the STAIR group has met six times discussing and revising their recommendations for preclinical and clinical stroke trials (Fisher 2003; Fisher 2005; Fisher et al. 2009; Fisher et al. 2007; Saver et al. 2009; STAIR Group 1999; STAIR Group 2001). Recommendations provided by the STAIR consortia emphasize the design quality of both experimental and clinical stroke trials. With respect to experimental animal stroke trials, STAIR recommendations have highlighted the need for investigators to consider factors such as species and gender differences, clinical relevance of animal models, dose-response determinations, therapeutic time windows, blood-brain-barrier (BBB) permeability and tissue drug levels, treatment randomization, physiological monitoring, and at least 2 outcome measures covering both acute and long-term endpoints.

The STAIR criteria should be used with caution because there may be conflicts between its suggested late treatment and therapeutic windows.

In the STAIR I, the ideal neuroprotective drug trial was described thus: “should demonstrate efficacy in at least 2 species, in at least 2 laboratories that use different models, is effective in both permanent and transient focal ischemia, and improves short-term and long-term histological and functional outcomes, even when administered several hours after the onset of ischemia” (STAIR Group 1999). Keeping the therapeutic window in mind, it may be simply impossible to demonstrate robust neuroprotection when the treatment is delivered too late. The therapeutic window is roughly a few hours in rodent MCAO occlusion (MCAO) models. For example, in a 300 g rat, a 2-hour duration of transient MCAO produces a large infarct volume of 400-450 mm³, which is similar in size to the infarct caused by permanent MCAO after 24 hours (Greco et al. 2007; Masada et al. 2001). Hence, it is likely that a preclinical stroke trial using a 2 hour transient MCAO model and a late treatment time point (e.g., 6h post-MCAO) (Simard et al. 2009; Yin and Zhang 2005) would have missed the therapeutic window and the opportunity to observe a treatment effect. In this instance, a baseline injury quantification study, performed at different treatment time points (e.g., 2, 4, 6 hours post-MCAO) would improve study design and increase the chance of obtaining a positive neuroprotective effect. Some histopathological methods and diffusion-weighted imaging techniques described in the infarct volume measurement section of this guideline can be used for the detection and quantification of baseline injury starting several hours after ischemia.

The STAIR criteria should be used with caution because there may be conflicts between its suggested observational time and the natural history of stroke evolution.

As discussed in more detail below, both the infarction evolution and changes in functional deficits have their own natural histories. Measuring infarct volume evolution is time sensitive and methodology dependent (see section on Infarction volume measurement). Assessment of functional recovery is even more complicated, is model dependent, and is time sensitive in relation to the recovery pattern and functional test being used (see section of Functional evaluation). Therefore, it may sound arbitrary to recommend all outcome measures be performed in 1-3 days and in 7-30 days.

Would the STAIR criteria help with increasing the chance of a true discovery (no, but this was not really its aim)?

As stated in the STAIR I, the purpose of STAIR is “to propose recommendations for ways to optimally preclinically assess neuroprotective and restorative drugs for acute ischemic stroke”. However, these recommendations were condensed into a few designing principles even with the latest update (Fisher et al. 2009), which has been functioning like an elevated threshold limiting experimental discovery entering into clinical trials. These STAIR criteria may help with improving the design quality of preclinical stroke trials, reducing bias and false positive conclusions (Fisher et al. 2009), but has little to do with increasing the chance of scientific discoveries. It is the research direction that holds the chance of scientific breaking through while the optimized methodologies increase the sensitivity for positive findings. The research directions that hold the continued promise for neuroprotection for ischemic stroke has been discussed in our previous review paper (Liu and Levine 2008). Optimization of preclinical stroke trials is more complicated than that the STAIR has recommended, which is what we need to address in this stroke model guidelines

4. STROKE MODEL SELECTION

Various stroke models have been developed to mimic different stroke subtypes or pathological mechanisms and can be generally classified into two categories: focal cerebral ischemia models and global cerebral ischemia models. Global ischemia models mimic the clinical conditions of brain ischemia following cardiac arrest or profound systemic hypotension, focal models represent ischemic stroke, the most common clinical stroke subtype. The most commonly used focal ischemia models are the intraluminal filament model (Koizumi et al. 1986) and the Tamura model (Tamura et al. 1981a). Some additional stroke models involve special mechanisms to induce artery occlusion/ischaemia, such as the thromboembolic, endothelin and photochemical models.

GUIDANCE

There are mainly two factors that influence the selection of in vivo stroke models for preclinical trials. These are the potential protection mechanism of the neuroprotective candidate and the highest achievable model quality with a particular lab setting.

For examples, if the candidate is predicted to reduce ischemic injury by attenuating cerebral edema after thrombolytic therapy, the thromboembolic model should be used; if the predicted neuroprotection is associated with a particular brain cortex region, the photochemical model will be

preferable because this model is able to produce ischemic injury in an arbitrary geometric shape at any location on the brain surface. If the predicted protection mechanism of a drug candidate is shared by several stroke models, the selection of a preferred model could be determined by the achievable model quality, as judged by success rate and outcome consistency. In most cases, the choice is between the intraluminal model and the Tamura model.

TABLE 1. SUMMARY OF STROKE MODEL SELECTION

Stroke model	Preferred application	Reference
Photochemical model	Neuroprotection is associated with a particular brain cortex region. Free radicals and endothelial injury play major roles in lesion development.	(Chen et al. 2004; De Ryck et al. 1996; De Ryck et al. 1989; De Ryck et al. 2000; Eichenbaum et al. 2002; Futrell et al. 1988; Lozano et al. 2007; Ostrovskaya et al. 1999)
Autologous clot model	Clot-related protection mechanisms.	(Beech et al. 2001; Busch et al. 1997; Harada et al. 2005; Kano et al. 2003; Kano et al. 2005; Kilic et al. 1998; Krueger and Busch 2002; Orset et al. 2007; Romanos et al. 2007; Tejima et al. 2001; Toomey et al. 2002; Vosko et al. 2003)
Endothelin-1 model	Transient to semi-permanent focal cerebral ischemia that need outcome measurements of both histology and neurofunctions	(Biernaskie et al. 2001; Horie et al. 2008; Nikolova et al. 2009; Windle et al. 2006)
Tamura model	Permanent focal cerebral ischemia. Transient focal cerebral ischemia in which functional assessment is not needed.	(Bederson et al. 1986b; Buchhold et al. 2007; Chen et al. 1986; Roof et al. 2001)
Intraluminal model	Permanent and transient focal cerebral ischemia that need outcome measurements of both histology and neurofunctions	(Candelario-Jalil et al. 2008; Khan et al. 2006; Liu et al. 2006; Shimamura et al. 2006a; Shimamura et al. 2006b; Solaroglu et al. 2006; Tsubokawa et al. 2007; Tsubokawa et al. 2006a; Tsubokawa et al. 2006b)

SUPPORTING DISCUSSION

About the photochemical model

Implementation of the photochemical model involves injection of a photosensitive dye that penetrates the BBB. The photochemical reaction produces singlet oxygen and free radicals, which causes endothelial injury and formation of microthromboses. The light used for inducing this reaction can be laser or filtered non-laser light, and can be shone onto a section of artery wall or any location of the skull. Therefore, this model is useful for neuroprotection that is associated with a particular brain cortex region and involves free radical scavenging as a protective mechanism (Chen *et al.* 2004; De Ryck *et al.* 1996; De Ryck *et al.* 1989; De Ryck *et al.* 2000; Eichenbaum *et al.* 2002; Futrell *et al.* 1988; Lozano *et al.* 2007; Ostrovskaya *et al.* 1999).

About the autologous clot model

Although the autologous clot model that mimics thromboembolic stroke has been developed (Kudo *et al.* 1982), and efforts have been made to improve its outcome consistency, (Wang *et al.* 2001; Zhang *et al.* 1997b) this model is still not suitable for validating neuroprotective effects because of its uncontrollable reperfusion and unacceptable variation of infarct area (Wang *et al.* 2001; Zhang *et al.* 1997a; Zhang *et al.* 1997b). Therefore, this model is re-

served for clot-related protection mechanisms which other stroke models cannot address.

About the endothelin-1 model

Endothelin-1 (ET-1) is a potent vasoconstrictor. It reduces regional cerebral blood flow and produces ischemic injury when being injected directly into brain tissue (Windle *et al.* 2006) or adjacent to the MCA (Biernaskie *et al.* 2001; Nikolaova *et al.* 2009). The magnitude and duration of reduction of cerebral blood flow is variable, dose dependent (Nikolaova *et al.* 2009), and strain dependent (Horie *et al.* 2008), persistent up to 7-16 hours (Biernaskie *et al.* 2001). ET-1 has a much less potent effect for producing an infarct in mice than in rats (Horie *et al.* 2008).

Intraluminal model versus Tamura model.

In experienced hands, the intraluminal model and the Tamura model can achieve similar success rates and outcome consistency (Table 2). However, some types of the Tamura model may cause just cortical injury with small infarction volume, which does not produce consistent functional deficits (Chen *et al.* 1986; Roof *et al.* 2001).

TABLE 2. COMPARISON OF THE INTRALUMINAL MODEL AND THE TAMURA MODEL

Model	Intraluminal	Tamura
Need for craniotomy	No	Yes
Incur brain trauma	No	Yes
Occlusion methods	Monofilaments: heat/flame blunted PLL coated Silicone-rubber coated	Microclips Suture tying Suture/wire retraction Electrocoagulation
Success rate for transient MCAO	60-100%	40-75%
Infarct distribution	Basal ganglia and cortex	Depending on occlusion site. Only cortical infarct occurs if occlusion site is lateral to the olfactory tract
Reported best pSDM	10-20% in rats 5-10% in mice	6.6-16% in rats 10-13% in mice
Functional deficit	Severe and consistent	Mild and inconsistent, especially when the infarct is limited to the cortex

For detailed discussion of Tamura model and intraluminal model please refer to the related sections below.

5. THE INTRALUMINAL MODEL

For the intraluminal model, the key factors that affect outcome consistency are **the physical properties of the occluder, the MCAO surgical procedure** and the strain of animal. Critical physical properties of the occluder that affect stroke outcome include its tip diameter, tip length, tip shape, and flexibility. Some specific surgical procedures have also been developed for different purposes, such as for confirming a successful occlusion, for supplemental occlusion of proximal arteries, and for prevention of premature reperfusion. Animal strain is not the focus of the first version of SMG.

A. THE SELECTION OF MCAO OCCLUDERS

GUIDANCE

It has been shown that silicone-rubber coated filaments are superior to flame blunted and PLL coated monofilaments for producing consistent ischemic injury (Spratt et al. 2006). There are insufficient data for an accurate comparison between silicon rubber coated monofilaments and glue-coated, resin-coated or nail polish-coated monofilaments. Flame/heat-blunted and PLL coated monofilaments are generally considered unacceptable for neuroprotection studies because of their low success rate, high subarachnoid hemorrhage (SAH) rate, and large variability in infarction volume.

SUPPORTING DISCUSSION

The intraluminal MCAO models can be induced using different filaments. In the Koizumi model, a silicone-rubber coated monofilament is used, while in the Longa model a flame-blunted monofilament is used. Other occluders include the poly-L-Lysine (PLL) coated monofilament (Spratt *et al* 2006), methyl methacrylate glue coated monofilament (Shah *et al* 2006), silicon resin coated monofilament (Yamauchi *et al* 2005), and nail polish coated monofilament (Matsushima and Hakim 1995). The physical characteristics of the occluder influence outcome variation by causing insufficient occlusion, premature reperfusion, and/or filament dislodgement. The following paragraphs review the MCAO model quality obtained using the most common occluders and their optimizations.

The PLL coated occluders.

The PLL coated monofilament has the lowest success rate, the highest SAH rate and highest mortality rate among all monofilaments in rat models. MCAO models using PLL coated occluders have been reported to have a success rate as low as 13-14% in rats, with model mortality of around 21-31% (Spratt *et al* 2006). High mortality (50-60%) and infarct size variation have also been reported when using PLL coated sutures in mouse models (Huang *et al* 1998). While most authors reported low success rates, high SAH rates, and high mortality rates when using PLL coated sutures for both rat models and mouse models, Belayev *et al* reported increased infarct volume and experimental consistency as compared to uncoated sutures, although in some instances brain infarction did not occur (Belayev *et al* 1996).

Flame/heat-blunted occluders.

Tsuchiya *et al.* (Tsuchiya *et al* 2003) showed that using flame blunted monofilaments to induce MCAO caused a 40% rate of subarachnoid hemorrhage, and pSDM was greater than 100%. In another study (Schmid-Elsaesser *et al* 1998), models using heat-blunted 3-0 filaments had a success rate of 46% (without further repositioning of the occluder according to laser Doppler flowmetry (LDF) monitoring), with 44% occurrence of SAH. Premature reperfusion occurred very frequently with a rate of 24% when using the heat-blunted filament group as shown through LDF monitoring (Schmid-Elsaesser *et al* 1998). The authors' own experience confirmed a less than 40% success rate when using flame blunted monofilaments. Personal communication with other MCAO model performers who have experience with the Longa model confirm that a flame blunted occluder is not an acceptable choice for neuroprotection studies. In the mouse intraluminal model, SAH rates can reach as high as 40% if uncoated heat-blunted filaments are being used. In such cases, the pSDM can be more than 50% (Tsuchiya *et al* 2003).

Silicone-rubber coated occluders.

Studies using silicone rubber coated monofilaments have reported success rates ranging from 66% (Schmid-Elsaesser *et al* 1998) to 100% (Liu *et al* 2006), and SAH rates from 0% (Chen *et al* 2008) to 8% (Schmid-Elsaesser *et al* 1998). Premature reperfusion rates have been reported to be 26%; readjusting filament location for correcting premature reperfusion could increase the success rate of MCAO (Schmid-Elsaesser *et al* 1998). The pSDM when using a silicone-rubber coated filament ranges from 30% (Schmid-Elsaesser *et al* 1998) to around 5% (Maysami *et al* 2008). It also seems that bilateral laser Doppler flowme-

try can be a useful tool for detecting premature reperfusion (Hungerhuber *et al* 2006).

B. OPTIMIZATION OF MCAO OCCLUDERS

GUIDANCE

*The physical properties of the occluder tip play a critical role in causing infarct variation and SAH occurrence. For a certain range of animal body weights, an optimal occluder diameter can be found through a series of pilot experiments. It has been reported that the optimal occluder diameter for rats weighing 275-320g is around 0.38 mm for silicon rubber coated monofilaments (Spratt *et al* 2006). The silicone rubber coating length is another important factor that influences the occluder's ability to block the back-flow from communicating arteries (Chen *et al* 2008). Therefore, an optimal coating length may also exist for animals within a certain body weight range, so matching the occluder size with animal size would theoretically improve model consistency. Note too that a shorter coating can preserve blood supply to the hypothalamus, minimizing post-surgical thermoregulatory dysfunction, particularly the occurrence of spontaneous hyperthermia. In order to match the wide range of rodent animal body weights, a large number of different occluders in standard size would be needed. To this end, our recommendation is to obtain commercially made occluders, which are available in different diameters and silicone rubber coating lengths (www.doccol.com).*

SUPPORTING DISCUSSION

When the occluder is matched to animal size, improved success rates and reduced SAH rates can be achieved.

In rat models of 60-min transient MCAO to 24-h permanent MCAO using correct-sized occluders (Candelario-Jalil *et al*. 2008; Khan *et al*. 2006; Liu *et al*. 2006; Shimamura *et al*. 2006a; Shimamura *et al*. 2006b; Solaroglu *et al*. 2006; Tsubokawa *et al*. 2007; Tsubokawa *et al*. 2006a; Tsubokawa *et al*. 2006b), the success rate was found to be 88-100%, and the SAH rate to be 4%. In mouse models of 60-min transient MCAO (Chen *et al*. 2008; Kleinschnitz *et al*. 2007; Maysami *et al*. 2008; Pignataro *et al*. 2007b; Pignataro *et al*. 2007c), the success rate was found to be 96% and the SAH rate 0%.

When the occluder is matched to animal size, impressive improvements in infarct consistency have been reported both in rats and in mice.

A technical paper by Shimamura showed consistent infarction and a tight error bar in rat models even with inexpe-

rienced surgeons (Shimamura *et al*. 2006a). For a 60-min to permanent occlusion in rats, the pSDM is around 10% to 20% depending on experimental design and selection of right-sized filaments. (Candelario-Jalil *et al*. 2008; Khan *et al*. 2006; Liu *et al*. 2006; Shimamura *et al*. 2006b; Solaroglu *et al*. 2006; Tsubokawa *et al*. 2007; Tsubokawa *et al*. 2006a; Tsubokawa *et al*. 2006b). A 15-min occlusion could also produce a consistent caudate infarction with little variation in mice (Pignataro *et al*. 2007a). For a 30-min occlusion, the pSDM was reported to be around 20% in mouse models (Cho *et al*. 2007; Kim *et al*. 2008). Even better consistency has been reported in 60-min MCAO models in mice, in which the pSDM was around 5-10% (Kleinschnitz *et al*. 2007; Maysami *et al*. 2008; Pignataro *et al*. 2007b; Pignataro *et al*. 2007c).

Standard-sized occluders are available for matching with animal size.

Varying sized occluders can be conveniently obtained commercially (www.doccol.com) with desired tip diameter and silicone rubber coating length. Tip diameter can be selected within a range from 0.17 mm to 0.49 mm and the coating length in a range from 2 mm to 10 mm. This makes it possible to match animal body weight with occluder diameter so as to achieve better results. Although there is not enough available data to make a detailed match chart between occluder size and animal size, a preliminary matching chart is provided by the vendor to guide investigators' selection of occluders, covering animal body weights from 15 to 400 grams.

C. OPTIMIZATION OF SURGICAL PROCEDURES

GENERAL GUIDANCE

The surgical procedure of inducing MCAO models plays an important role in the stroke outcome variation; and it can be optimized to achieve better success rates and reduce outcome variation. Modifications and optimizations have also been reported concerning the inserted distance of the MCA occluder, CAA approach versus ECA approach, and supplemental occlusion of proximal arteries.

SPECIFIC GUIDANCE ON KEY SURGICAL STEPS

The inserted distance of the MCA occluder.

GUIDANCE: The inserted distance of the occluder is critical to a model's success. For the rat model, the distance from the common carotid artery (CCA) bifurcation is 18-20 mm for a 300 g (Belayev *et al*. 1996; Lee *et al*. 2004), and 20-22 mm for a 400 g rat (Lindner *et al*. 2003). For the mouse model, a distance of 9-11 mm (Dimitrijevic *et al*.

2007; Yamashita *et al*. 2006) rostral to the CCA bifurcation needs to be reached.

SUPPORTING DISCUSSION: It has been reported that different insertion distances produce significant differences in infarct size (Zarow *et al*. 1997). Over-insertion may cause a rupture of the anterior cerebral artery (ACA) and subsequent SAH whilst insufficient insertion may not be able to block the back-flow from the anterior communicating artery, leading to incomplete occlusion of the MCA.

In vivo confirmation of MCA occlusion.

GUIDANCE: A reduction in regional cerebral blood flow (rCBF) of at least 75% from baseline is generally accepted as an indicator of successful MCAO (Schmid-Elsaesser *et al*. 1998).

SUPPORTING DISCUSSION: Because of the anatomic variation of carotid arteries between individuals and between strains (Dittmar *et al*. 2006; Oliff *et al*. 1995a; Oliff *et al*. 1995b), and inaccuracies in measuring the inserted distance, investigators often use LDF to instantly confirm successful occlusion of the MCA. Due to neck movement or artery wall retraction, the occluder may dislodge from its original location if it is not properly affixed against the arterial wall. Occluder dislodgement can result in premature reperfusion and SAH. For reducing occluder dislodgement, investigators have used various techniques. The smooth nylon surface of the occluder at the affixation position can be made serrated to increase traction. A microclip with proper biting force or a tight knot applied onto the artery and the serrated occluder section may help reducing dislodgement.

CAA approach versus ECA approach.

GUIDANCE: The ECA approach is a better choice for transient MCAO because it maintains the anatomic integrity required for reperfusion. The CCA approach may, on the other hand, be a simpler surgical procedure for permanent MCA occlusion.

SUPPORTING DISCUSSION: When inducing MCA occlusion, the occluder may be introduced into the internal carotid artery (ICA) via a cut in the CCA (the CCA approach) or a cut in the external carotid artery (ECA). Most intraluminal models that appear in the literature were induced through the ECA approach. Some stroke investigators introduced the occluder through an arteriotomy of the common carotid artery (Wetzel *et al* 2008; Xi *et al* 2004). The CCA approach changes the dynamics of cerebral blood flow when the occluder is withdrawn for reperfusion because blood flow will enter only from the contralateral side through the Circle of Willis. Changes in proximal blood supply may also affect infarct volume and model consistency. Studies have

shown that occluding additional proximal arteries along with MCA can achieve a larger and more consistent infarct (Woitzik *et al* 2006).

Supplemental occlusion of proximal arteries

GUIDANCE: Supplemental occlusion of proximal arteries (PTA and/or CCA) decreases infarct volume variation.

SUPPORTING DISCUSSION: When the MCA is being occluded, there may be residual blood flow to the MCA territory, which causes insufficient occlusion of the MCA. Residual blood flow could come from the anterior and posterior communicating arteries (AComA and PComA) of the Circle of Willis, the ICA itself, or from leptomeningeal anastomoses on the cortical surface (i.e., collateral supply). Blood flow can also reach the MCA cortex indirectly by external carotid collateral flow through the pterygopalatine artery. Applying a vessel clip on the CCA can increase infarction volume by reducing the residual blood flow through the ICA, especially when smaller filaments are being used (Tsuchiya *et al* 2003). A more recent study has shown that blocking pterygopalatine artery (PTA) blood flow decreases infarct volume variation (Chen *et al* 2008). However, from an anatomical perspective, these surgical modifications will not be effective in reducing the residual flow originating from AComA, PComA, or leptomeningeal anastomoses. A more practical option is to use optimized, silicone rubber-coated, standard-sized monofilaments, which match animal body weight, to induce MCA occlusion.

6. THE TAMURA MODEL

In 1981, Tamura described a rat model of middle cerebral artery occlusion (Tamura *et al* 1981a; Tamura *et al* 1981b) which can induce either permanent or temporary occlusion of the MCA. The former could be achieved by direct electrocoagulation of a section of the MCA whereas the latter by either microclip application or artery ligation/retraction by a nylon suture or a rigid wire. In recent years, infarct variation with the intraluminal models has been noticed (Chen *et al* 2008; Shimamura *et al* 2006a), and has become a concern in preclinical neuroprotective trials, especially with suboptimal models (Savitz 2007). Using just one rodent model may not be sufficient for screening neuroprotective candidates in preclinical stroke trials. Therefore, the Tamura model may serve as a supplemental or alternative approach for validating neuroprotective efficacy in rodents.

A. ABOUT THE MCA OCCLUDER

GUIDANCE

The MCA occluder and occlusion mechanism play no role in the Tamura model. A careful selection of microclips will be necessary for reducing artery wall mechanical injury.

SUPPORTING DISCUSSION

Similar success rates and stroke outcome consistency can be achieved with different occluders and occlusion techniques, such as electrocoagulation, applying a microclip, or suture ligation. Model success rate, mortality rate, and infarct variation will differ in response to changes of occlusion site, occlusion extensiveness, ischemia duration, CCA occlusion, and the animal's blood pressure.

Microclips with a biting force not greater than 15 g are usually used. The size, weight, and biting force of the microclip are important for a successful Tamura model. Not all microclips are suitable for rodent MCA occlusion. Microclips that have been used in this model include Codman Sundt AVM microclip #1-3, Zentye microclip, and Scoville Lewis clip.

B. SURGICAL OPTIMIZATION

GUIDANCE

*Ensuring a complete occlusion of the MCA is a necessary step for this model. In addition, the occlusion site and extensiveness must remain consistent. In the transient MCAO model, simultaneous occlusion of either common carotid artery increased the model success rate (Coert *et al* 1999). On the other hand, MCAO combined with bilateral CCAO should be used with caution because of a higher incidence of mortality. Moreover, transient MCAO by the Tamura model is often suboptimal and should be used with caution.*

SUPPORTING DISCUSSION:

Visual inspection under a stereo microscope is commonly used for this purpose. Even with an ensured occlusion through transection of the MCA, infarct consistency still largely depends on the length of coagulated MCA (Bederson *et al* 1986b).

Bederson *et al* first reported (Bederson *et al* 1986b) the correlation of success rate with the anatomic location where the MCA is occluded. In their experiments, a 100% success rate was achieved with 3 or 6 mm occlusion of the MCA beginning proximal to the olfactory tract. 1-2 mm occlusion of the MCA from its origin, at the olfactory tract, or lateral to the inferior cerebral vein, however, only produced infarction in 13%, 67%, and 0% of rats, respectively.

When assessed at 3 days post surgery, one hour MCAO only caused cerebral infarction in 40% of rats; with simultaneous occlusion of ipsilateral or bilateral CCAs, the suc-

cess rate reached 60% and 75%, respectively. A higher success rate was also observed when the duration of MCA occlusion increased. One hundred percent success rate was observed with permanent MCAO plus bilateral CCAO.

Chen *et al* reported (Chen *et al* 1986) that the mortality rate could reach 60% when the CCAs were permanently ligated bilaterally; the high mortality could be reduced to 7% if the contralateral CCA was released after 60-min of occlusion.

Although transient direct MCA occlusion with subsequent reperfusion is possible by applying a microclip on, or suture tying, the MCA, the implementation of these techniques demands extremely delicate surgical skills, especially in mice. Consequently, this model has gradually become less popular since the emergence of the intraluminal model of transient MCAO (Koizumi *et al* 1986), which is relatively easier to perform and does not require a craniotomy.

C. PURE CORTICAL INFARCTION VERSUS COMBINED INFARCTION

GUIDANCE

*Pure cortical infarcts in this model produce very mild and inconsistent functional deficits and are therefore not suitable for functional recovery evaluation. Permanent occlusion at a site proximal to the lenticulostriate branches (pMCAO) produces a larger infarct with more persistent functional deficits (Roof *et al* 2001), and may be preferable for assessing a robust protective effect of therapeutic agents for stroke.*

SUPPORTING DISCUSSION

The site of MCA occlusion has also been shown to influence the severity and consistency of histologically-revealed damage as well as functional deficits. Occlusion of the MCA lateral to the olfactory tract produces a pure cortex infarction because the basal ganglia blood supply from the lenticulostriate branches is spared; occlusion of the MCA at its origin produces a combined infarction including both cortex and basal ganglia. Microclips and retraction/release methods are used for transient MCAO/reperfusion and produce a pure cortical infarct due to operational limitation. Electrocoagulation necessarily produces permanent occlusion; it can be applied at various sites along the MCA to produce a variety of lesions from a pure cortical infarct to combined infarcts of both basal ganglia and cortex.

D. INFARCT VOLUME VARIATION AND OPTIMAL ISCHEMIA DURATION

GUIDANCE

Transient MCA occlusion of 30-min by the Tamura model is too mild to produce a brain infarct, but selective neuronal damage in the striatum and subcortex areas in the ipsilateral side could be observed (Yang et al 2001). A 3-h occlusion time is preferable for transient cortical ischemia because of increased consistency. Infarct volume consistency could be improved with supplemental CCA occlusion. Similar results have been reported with different occlusion methods.

SUPPORTING DISCUSSION

Improved infarct consistency has been reported with simultaneous occlusion of the common carotid arteries (Coert *et al* 1999). For example, the pSDM for 1-h MCAO was 200%, 1-h MCAO plus ipsilateral CCAO was 133.5%, and 1-h MCAO plus bilateral CCAO 100.9%. The pSDM for 3-h MCAO plus bilateral CCAO was 59%. The best consistency was observed with permanent MCAO plus bilateral CCAO with the pSDM being 43.75%.

A pSDM range of 10% to 160% has been reported when using a Zen-type microclip for direct MCA occlusion in rats. Margaille *et al* achieved excellent consistency in rats, with a pSDM of 10% for striatum infarcts and 15-16% for cortex infarcts in transient MCAO of 60-90 min (Margaille *et al* 1996). However, in a 1-h MCAO model, David *et al* reported significant variation with the pSDM being 68% (David *et al* 1996). Morikawa *et al* reported an even higher pSDM of 160% for cortex infarcts and 83% for striatum infarcts with a 2-h transient MCAO (Morikawa *et al* 1992). Using a Zen-type microclip for MCA occlusion in mice seems to result in less variation than in rat models. Kitagawa *et al* achieved a pSDM of 10% for permanent MCAO, and of 45.65% for 60-min transient MCAO (Kitagawa *et al* 2004).

When proximal arteries were occluded in addition to microclip occlusion of the MCA, a pSDM range of 16% to 119% could be achieved. Using a Sundt microclip for direct MCAO plus bilateral CCAO, Buchan *et al* (Buchan *et al* 1992) achieved pSDMs of 119%, 86% and 16% for 1-h, 2-h, and 3-h transient MCAO respectively, when combined with the same duration of contralateral CCAO and permanent ipsilateral CCAO, in normotensive rats. A pSDM of 32% could be reached for 24-h permanent MCAO combined with permanent bilateral CCAO. In a 3-vo transient MCAO model with all three vessels released at the same time after a period of occlusion, the pSDM was 38% (Schielke *et al* 1999) for 3-h transient MCAO, and 32% (Coert *et al* 2003) for 2-h transient MCAO. In hypertensive rats, a 90-min transient MCAO combined with permanent occlusion of the ipsilateral CCA can produce a consistent infarct volume with a pSDM of 25% (Colbourne *et al* 2000).

Using suture tying methods in rats, the pSDM range has been reported as being from 13% to 99%. Selman *et al* reported the pSDM in a 1-h transient MCAO model to be 99% (Selman *et al* 1994). Better consistency could be achieved by increasing the duration of MCA occlusion. Permanent MCA ligation combined with permanent ipsilateral CCA ligation and transient 60-min occlusion of the contralateral CCA (Chen *et al* 1986) produced a pSDM of 19%. Infarct variation coefficients of 13% have been reported (Drummond *et al* 1995) with 3-h transient MCAO in hypertensive rats.

For MCA cauterization and permanent cut methods, a pSDM range of 6.6% to 149% has been reported. Morikawa reported a pSDM of 53% for cortex infarcts and 34% for striatum infarcts (Morikawa *et al* 1992). In a permanent distal MCAO model with ipsilateral CCA occlusion, Brint *et al* also reported (Brint *et al* 1988) a pSDM of 16-149% in Wistar rats and 6.6-35% in spontaneously hypertensive rats, which was associated with a more severe infarct in Wistar rats.

A pSDM range of 12.5% to 50% could be reached in a 3-vo Tamura model. Yanamoto *et al* evaluated a 3-vo model both in normotensive rats and mice, in which the MCA was cauterized and cut permanently, along with temporary bilateral CCAO (Yanamoto *et al* 2003). When the CCAs were released after 60-min, the pSDM reached 50% in rats and 24% in mice. When the CCAs were released at 2-h post occlusion, the pSDM in rats was reduced to 12%; this is an improvement over their earlier work which described (Yanamoto *et al* 1998) a pSDM of 22% in a 3-vo transient MCAO of 2-h in normotensive rats (all three vessels were released after 2-h occlusion).

7. INFARCTION VOLUME MEASUREMENT

A. METHODS FOR INFARCTION VISUALIZATION

Measuring infarct volume evolution is time sensitive and methodology dependent. Tissue processing for histopathological staining may produce significant volume variation. Definitive determination of cerebral infarct is made by microscopic examination of hematoxylin and eosin (H&E) stained brain sections. Infarcted brain tissue appears as a sharply delineated pan-necrotic area on H&E stained brain sections (Garcia *et al* 1993). On H&E stained brain sections ischemia-induced neuronal morphological changes can be detected within a few hours after MCA occlusion while it usually needs 24-h for these ischemic changes to mature into a well-developed infarct. There are other more sensitive staining methods that can detect ischemic injury

as early as 15-min post MCA occlusion. These staining methods include the arginophilic III staining (Czurko and Nishino 1993; Liu and Guo 2000a) and the immunohistochemical staining of microtubule-associated protein 2 (MAP2) (Pettigrew *et al* 1996). The early infarct area revealed using the above-mentioned pathological methods does not usually have enough contrast when compared with adjacent non-ischemic tissue. This makes it difficult for direct macrometric measurement of infarct volume. Alternatively, the macrometric measurement of infarct volume can still be achieved after microscopic delineation of the infarct area (Liu and Guo 2000b). The above mentioned methods also require tissue fixation followed by a complex staining process, which may produce 7-12% variation of hemisphere volume (Overgaard and Meden 2000). Therefore, a standard tissue processing protocol for these methods is needed for reducing variation. Currently, direct macrometric measurement of brain infarction is most often conducted by using 2,3,5-triphenyltetrazolium chloride (TTC) to stain fresh brain sections. The TTC staining method is able to offer a reasonably sharp contrast between infarcted and normal areas as early as 3-h in rats, and 12-h in mice. It is relatively simple to conduct and is widely accepted by most stroke investigators.

B. DIRECT VISUALIZATION OF INFARCT ON TTC STAINED FRESH BRAIN SECTIONS

GUIDANCE

TTC staining is the most widely used technique to identify infarcted versus viable tissue. It is not selective for brain tissue or cell types. A brain matrix or vibratome is necessary for providing clean cut sections. The extent of brain infarction is optimally seen between 24-36 h post ischemia by the staining of fresh brain sections. Species differences in mitochondrial dehydrogenases may account for differences in the times at which infarction can become apparent (see below). In vivo TTC staining should be used only for transient ischemic models in its reperfusion stage after excellent reperfusion has been ensured. Better contrast and infarct boundary delineation may be obtained with use of lower TTC concentration.

SUPPORTING DISCUSSION

TTC serves as a proton acceptor for many pyridine nucleotide-linked dehydrogenases (such as succinate dehydrogenase); it is reduced by these enzymes in viable brain tissue into a red, lipid-soluble formazan, while infarcted or non viable tissue remains unstained (Bederson *et al* 1986a; Liszczak *et al* 1984). The TTC method requires the brain to be sectioned into several thin parallel sections with even

surfaces for infarct volume calculation. It has been reported that there is good correlation between TTC, H&E (Bederson *et al* 1986a; Lundy *et al* 1986), and cresyl violet staining (Tureyen *et al* 2004). Although TTC staining is widely used for infarct volume measurement, there are some issues that need to be considered regarding its use.

Macrophage/glia infiltration may confound the staining results after 36-h post-ischemia. Infiltrating cells may cause staining in infarcted tissue. For example, 36-h after stroke, macrophages and glial cells infiltrate infarcted areas, and result in tissue TTC staining, which would not have been evident at an earlier time point (Liszczak *et al* 1984). Another issue that needs to be considered is the species difference of mitochondrial enzymes (Stewart *et al* 1998). For example, ischemic injury can be visualized as early as 3 hours after stroke in rats (Bederson *et al* 1986a; Liu *et al* 2004), but may require at least 12 hours in mice.

TTC is able to pass the blood-brain barrier, which allows *in vivo* staining (Isayama *et al* 1991). However, such *in vivo* staining relies on the regional cerebral blood flow (Dettmers *et al* 1994), and may only be suitable for transient cerebral ischemia at the reperfusion stage; it cannot be used in permanent cerebral ischemia (Benedek *et al* 2006).

The TTC staining process is affected by several factors, such as TTC concentration, staining duration, and incubation temperature. A methodology paper (Joshi *et al* 2004) demonstrated that staining with lower TTC concentration (0.05-0.1% versus 0.6%) at 37°C for 30-min could reduce non-specific staining and improve contrast between infarcted and normal tissue, and hence provide better delineation of infarct boundaries.

C. DIGITAL METHODS FOR DEFINING THE INFARCTED AREA

GUIDANCE WITH SUPPORTING DISCUSSION

*The traditional way of acquiring a digital image of brain infarct is to digitalize the brain section through a stereoscope equipped with a macro lens. TTC-stained brain sections can also be scanned into digital files for automated infarct recognition (Goldlust *et al* 1996). Manual delineation of the infarct area may be needed if the contrast is insufficient for an automatic infarct selection. Due to field limitation of the regular objective lens, additional optical modification may be required in order to be able to view the entire brain section with a regular microscope. For volume calculation, the infarct area must have enough contrast against the non-infarcted area that it can be distinguished from its surrounding areas. *Infarct area can be measured using imaging analyzing software* such as Image Pro Plus (Liu *et al* 2006), Adobe Photoshop (Horita *et al* 2006), NIH image*

J (Tureyen *et al* 2004), or other appropriate image processing programs. If the contrast is excellent, as it usually appears on TTC stained sections, the infarct area can be automatically selected and calculated based on color differentiation. With spatial calibration the infarct area can be expressed in real measurement units (e.g., mm³).

D. CALCULATION OF INFARCT VOLUME

GUIDANCE

When comparing infarction volumes at different time points, cerebral edema and infarct shrinkage should be corrected for.

SUPPORTING DISCUSSION

Ischemic infarction evolution involves different temporal-spatial pathological processes that may influence infarction volume measurement. Studies on the natural progress of infarct evolution show significant differences in infarction volume between early and late time points (Gaudinski *et al* 2008; van der Worp *et al* 2005). Cerebral edema is more severe 2-3 days after acute stroke. Edema may significantly increase the brain tissue volume as well as the directly measured infarct volume. On the other hand, when an infarct has been evolving for one week, it will begin to shrink because of attenuated edema, tissue loss, and scar contraction. When comparing infarction volumes at different time points, cerebral edema and infarct shrinkage should be adjusted. In this situation, a corrected infarction volume against edema or shrinkage (Leach *et al* 1993; Lin *et al* 1993; Swanson *et al* 1990) will be more suitable.

E. CALCULATION FORMULAE FOR INFARCTION VOLUME

The following formulae can be used for calculating the corrected infarction volume for both edema and shrinkage.

Corrected infarct area = measured infarct area + area of contralateral corresponding structure – area of ipsilateral corresponding structure (Swanson *et al* 1990)

Corrected infarct area = measured infarct area x area of contralateral corresponding structure / area of ipsilateral corresponding structure (Leach *et al* 1993)

Infarction volume for continuous macrosections can be calculated as $\Sigma(\text{thickness} \times \frac{1}{2} (\text{corrected infarct area of a section's rostral surface} + \text{corrected infarct area of a section's caudal surface}))$

If the infarct volume calculation is based on thin microsections (5-10 μm thickness) at fixed interval, the formula will look like this:

Infarct volume = (interval + slide thickness) x (Σ (corrected infarct area) - $\frac{1}{2}$ corrected infarct area of the first slide - $\frac{1}{2}$ corrected infarct area of the last slide)

F. MEASUREMENT OF INFARCTION VOLUME VARIABILITY

GUIDANCE

Use relative volume for comparison between studies and indicate infarct volume variation.

SUPPORTING DISCUSSION

Experimental stroke models are performed with one or more of a variety of possible subject animals according to the needs of the study design. In addition, researchers measure infarct volume using different units and at various time points post ischemia. This situation generally precludes direct comparison of infarction volumes between studies. Standard deviation (SD) reflects the variability in a set of data while standard error of mean (SEM) reflects the accuracy of a mean value. Therefore the SD of infarct volume reflects the stroke model outcome variation. SD can be normalized to its corresponding mean as a Percentage of SD to Mean (**pSDM**). Some authors in the cited papers expressed data as mean \pm SEM; in these cases we have converted SEM to SD according to the formula $\text{SD} = \text{SEM} \times \text{SQRT } N$.

8. FUNCTIONAL EVALUATION

A. THE TIMING OF FUNCTIONAL EVALUATION

GUIDANCE

The natural process of functional recovery should be considered in functional evaluation after experimental focal stroke. Evaluation should be conducted at the same post-occlusion time point in all groups but not during the 6-12 hours post-occlusion because at this time accelerated functional recovery occurs. Maximal sensitivity for functional evaluation can be achieved between 2-6 hours post-occlusion.

SUPPORTING DISCUSSION

The extent of functional recovery after stroke is dependent on time, age and environmental factors (Buchhold *et al* 2007). Some functions recover faster and better than others. The most severe sensorimotor deficits can be observed at 2-6 hours post stroke with a fast recovering

speed being observed between 6-12 h post-MCAO (Reglodi *et al* 2003). For validating neuroprotective efficacy, functional tests with a slow or absent natural recovery process may be most appropriate, such as forelimb flexion, gait disturbance, and lateral resistance (Reglodi *et al* 2003). The well-known “circling phenomenon” can be observed as soon as the animal is fully recovered from anesthesia, but may not be apparent when evaluated at 24 hours in some stroke models (Erdo *et al* 2006) despite significant infarct volume maturation at this time. In a permanent MCAO model resulting in cortical infarction, it has been reported that most young rats (3-4 mo) do not show “circling” when evaluated on day 2 post ischemia (Buchhold *et al* 2007). Hence, such a highly time-dependent motor deficit may not be suitable for preclinical neuroprotection stroke studies. In order to achieve a better sensitivity in detecting neuroprotective efficacy, MCAO models of moderate severity should be used and appropriate functional tests should be conducted between 2-6 hours post ischemia because functional deficits usually reach maximum severity at this time. For confirming robust neuroprotection, functional tests that have a slow recovery pattern may be more appropriate.

B. EVALUATION SYSTEMS FOR NEUROLOGICAL FUNCTIONAL DEFICITS

GUIDANCE

Select an appropriate evaluation system to cover important functional deficits. It is reasonable to include more tests to cover different functional deficits and subsequently analyze both the total score and individual scores because each function has a different recovery pattern. Functional tests that have a slow recovery pattern may be most suitable to confirm a neuroprotective effect.

SUPPORTING DISCUSSION

Behavioral changes after ischemic stroke can be evaluated using specially designed scales. Many scales are available for the detection of ischemic injury, but not all scales can be used for the validation of an intervention’s neuroprotective capability. To qualify for neuroprotection studies, the neurological scale must be able to detect the major ischemia-induced behavioral changes, including motor, sensory, motion coordination, spontaneous activity, reflexes, consciousness, and alertness changes. Bederson’ 4-point scale (Bederson *et al* 1986b), modified Bederson’s scale (Becker *et al* 2001; Zausinger *et al* 2000), and Rogers’ 8-point scale (Rogers *et al* 1997), although frequently used, are primitive measurements of motor deficits. It may be more appropriate if these scales are merely used for confirming a successful occlusion of middle cerebral artery after completion of surgery. For a more informative func-

tional assessment, more complex evaluation systems like the 18 and 42 point scales should be considered (Chen *et al* 2001; Reglodi *et al* 2003). Although several functional tests have been developed to provide an effective neurological evaluation scale for preclinical neuroprotection studies (Buchhold *et al* 2007; Reglodi *et al* 2003; Schallert 2006), there are no guidelines regarding their use.

C. ANALYSES FOR NEUROLOGICAL FUNCTIONAL DEFICITS

GUIDANCE

Ensure a blind method is adhered to for conducting the evaluation process. Analyze both the total score and individual scores. When a complex battery of tests is being used, stratified analysis of functional deficits will be preferable because the changing pattern will be different in functional deficits. When indicated, use non-parametric statistical methods for data analysis.

SUPPORTING DISCUSSION

During the evaluation process, behavioral scores are given by the examiner based on the examiner’s observation and understanding of the tests; therefore, these scores are subject to the examiner’s bias. Adapting a blind method for functional evaluation will be necessary for reducing bias in preclinical neuroprotective trials. Moreover, the data set obtained from scaled neurological evaluation may not always conform to a normal distribution, especially when the sample size is small. Non-parametric statistical analyses should be used if the data can’t pass a normality test. For example, one should use a Mann-Whitney U test for two group comparison and a Kruskal-Wallis analysis of ranks for multiple group comparison.

9. ANESTHETICS

GUIDANCE

When designing a preclinical study for neuroprotection, the protection provided by anesthetics should be taken into account. When neurotransmitters or neuroplasticity are the main foci of a study, anesthetics such as urethane, which do not disturb the action of neurotransmitters should be used. Fasting animals should be utilized in the experimental design of neuroprotection studies though caution should be used to reduce hypoglycemia-related mortality when fasting small rodents (mice, gerbils).

SUPPORTING DISCUSSION

Many commonly used anesthetics have neuroprotective effects against cerebral ischemic injury. These anesthetics include isoflurane (Kawaguchi *et al* 2004; Xiong *et al* 2003), sevoflurane (Nakajima *et al* 1997; Payne *et al* 2005), desflurane (Erdem *et al* 2005; Tsai *et al* 2004), halothane (Haelewyn *et al* 2003), xenon (David *et al* 2008), nitrous oxide (Abiraini *et al* 2004; Haelewyn *et al* 2008), barbiturates (Warner *et al* 1996), propofol (Bayona *et al* 2004), ketamine (Proescholdt *et al* 2001), and the local anesthetic lidocaine (Siniscalchi *et al* 1998; Weber and Taylor 1994)..

Most anesthetics have been found to potentiate the inhibitory activity of the g-aminobutyric-acid (GABA)-A receptor. Volatile anesthetics are also antagonists of N-methyl-D-aspartate (NMDA) and amino-3-hydroxy-5-methyl-4-isoxazol-propionic acid (AMPA) receptors, and openers of K⁺ channels (Grasshoff *et al* 2005). Therefore, the working mechanism of anesthetics needs to be considered during the experimental design of neuroprotection studies (Maggi and Meli 1986; Sceniak and Maciver 2006). When an expected neuroprotection is likely via the opening of K⁺ channels, volatile anesthetics may have compounding effect and should be avoid when possible.

Hyperglycemic effects only occur in fed animals, and thus can be eliminated by fasting animals 18-24h before experimentation. Xylazine is an α 2-adrenergic agonist, which decreases plasma insulin level and induces hyperglacemia (Greene *et al* 1987; Thurmon *et al* 1984). Hence, xylazine should be avoided when blood glucose level becomes a concern in experimental design. In addition to xylazine's hyperglycemic effects, some commonly used volatile anesthetics, such as isoflurane and halothane, also may cause a rapid increase in blood glucose levels (up to 230 mg/dl or 12.6 mmol/L) within 20min of induction. Ketamine/xylazine can result in hyperglycemia reaching 290 mg/dl (15.9 mmol/L) (Saha *et al* 2005)..

10. TEMPERATURE

A. THE NECESSITY OF MONITORING TEMPERATURE

GUIDANCE

Controlling animal body temperature in a normal range is necessary for eliminating the protective effect of hypothermia and potential harmful effect of hyperthermia (Zaremba 2004).

SUPPORTING DISCUSSION

Brain temperature during hypoxia affects brain metabolism significantly (Winn *et al* 1981). Hypothermia reduces (Florian *et al* 2008; Miyazawa *et al* 2003; Ohta *et al* 2007) and

hyperthermia exacerbates (Kim *et al* 1996; Noor *et al* 2003; Noor *et al* 2005) ischemic brain injury, hence, fluctuation in animal body temperature will increase the variability of stroke outcome. Ischemia itself also affects post-ischemic temperature regulation, which in turn influences the extent and severity of brain injury and functional deficits (Colbourne *et al* 2000)..

B. MONITORING BRAIN/CORE TEMPERATURE

GUIDANCE

Various methods may be used for monitoring body temperature in stroke animal models. The simplest way of monitoring temperature is by placing a temperature probe in the rectum of the anesthetized animal. Monitoring brain or pericranial temperature may be performed with caution in some experiments when a difference between brain and rectal temperatures is predicted. Temperature monitoring should commence before inducing anesthesia and there is also a need to monitor temperature after surgery.

SUPPORTING DISCUSSION

Monitoring rectal temperature assumes that there are no, or at least there are predictable, differences between brain and rectal temperatures. However, brain temperature may actually be considerably different from rectal temperature during the ischemic period (DeBow and Colbourne 2003; Marion 2004; McIlvoy 2004; Nussmeier 2005). Pericranial temperature can be monitored by placing a subcutaneous needle thermistor adjacent to the skull in the temporal muscle, (Xiong *et al* 2003; Yonekura *et al* 2004) although it should be noted that this measurement is very sensitive to small changes in needle position. Alternatively, for experiments studying the effects of temperature changes during cerebral ischemia, a thermistor can be inserted directly into the brain (DeBow and Colbourne 2003; Menzel *et al* 1998). However, the latter method involves a relatively complex and invasive surgery to insert the brain probe, and runs the risk of causing brain injury and infection.

Hyperthermia or hypothermia can occur because of the surgery, anesthetic, ischemia, and/or unexpected infection. The use of telemetric temperature probes for monitoring post-ischemic body temperature has a significant advantage in its capacity to measure temperature continuously in conscious animals. In addition, telemetry can be used with an automated feedback system for temperature control. Disadvantages of this method are the high cost of telemetric systems and the need for additional surgery to implant probes.

C. MAINTAINING BRAIN/CORE TEMPERATURE

GUIDANCE

Maintaining core temperature within an appropriate range during ischemia can be achieved by using a water heating pad, electric heating blanket, heat lamp and/or heating fan. PID temperature controller equipped heating devices provide fast response and precise temperature control. Electric blankets are not recommended if a telemetric system is being used as they may interfere with the probe signal. Maintaining body temperature after surgery is necessary. This may be done by placing animals in a humidified warm chamber for a few hours.

SUPPORTING DISCUSSION

Since the thermal conduction of a water heating pad may not be rapid, an overhead incandescent lamp or heating fan may serve as a complementary heating source to further control temperature. It must be taken into consideration that the overhead heating source may interfere with the operation by heating the surgical tools and the operator's hands. Temperature control when using electric heating pads and blankets can be improved by using a proportional integral derivative (PID) temperature controller to allow *ex vivo* or *in vivo* feedback from the sensor that monitors heating pad or animal body temperature. The electric current to the heating pad can be either direct current (DC) or alternating current (AC), depending on the experimental design and budget. DC powered heating devices have less electric noise and are well suited for electrophysiological studies. AC powered heating devices may be used in most preclinical stroke trials that do not need electrophysiological monitoring.

Maintaining body temperature after surgery is just as important as during the ischemia period because the full recovery of animal body temperature regulation needs time (Chang *et al* 2008; Jia *et al* 2006). The most popular method of maintaining body temperature is by using a warm chamber that keeps the environmental temperature at 28–32°C. The considerable advantage of the thermo-controlled temperature regulation system with an *in vivo* feedback system, as described by Colbourne *et al* (Colbourne *et al* 2000), is that the investigator can regulate the temperature of conscious animals with precision during the post-ischemia period. Precise temperature regulation can be achieved with the automated telemetry system, which uses fine water mist with overhead fans for cooling and infrared lamps for heating.

11. MECHANICAL VENTILATION AND BLOOD GAS/GLUCOSE MONITORING

A. PROPER USE OF MECHANICAL VENTILATION

GUIDANCE

The importance of using mechanical ventilation should be determined by the anticipated impact of the surgical/anaesthetic procedure on respiratory function. The potential confounding effects from respiratory functional deficits can be minimized by the use of mechanical ventilation. Unnecessary use of mechanical ventilation should be avoided when a particular MCAO model is not likely to cause respiratory problems.

Ventilation may be needed when the operation lasts long (>1 hour) and when the ischemia affects brain stem function. A mixture of 30%:70% (O₂:N₂ or N₂O) may be used for preclinical stroke trials combined with individualised adjustment of ventilator parameters. The concentration of inspired oxygen and ventilator parameters (tidal volume, airway pressure, respiratory rate, inspiratory/expiratory duration) can be roughly determined by a pilot experiment with periodic measurements of arterial blood gases. The respiratory rate and stroke volume can be set differently in accordance with the different “dead space” of each ventilator and anesthetic circuit.

SUPPORTING DISCUSSION

Hypoxia is injurious to the CNS, especially the adult brain. Normobaric hyperoxia (Singhal *et al* 2002) and hyperbaric oxygen treatment (Iwatsuki *et al* 1994; Takahashi *et al* 1992; Wallsh *et al* 1986) have been demonstrated to be neuroprotective during ischemia and reperfusion, but also can have deleterious effects on the normal and injured central nervous system (CNS) (Bostek 1989; Bulte *et al* 2007; Diring 2008). Similarly, as carbon dioxide is a potent cerebral vasodilator and causes increased cerebral blood flow (CBF) (Kontos *et al* 1977a; Kontos *et al* 1977b; Rusyniak *et al* 2003), hypercarbia may have a protective effect during ischemia and reperfusion (Vornov *et al* 1996). On the other hand, extracellular acidosis caused by hypercapnia may inhibit neuronal functions (Velisek 1998) and cause adenosine triphosphate (ATP) depletion (Yamamoto *et al* 1997). In addition to the above, intubation and mechanical ventilation are commonly used to improve control of blood oxygen and carbon dioxide levels. However, the intubation procedure itself and control of the mechanical ventilation process are technically demanding and may cause tissue damage even in experienced hands. The use of mechanical ventila-

tion will mostly depend on the nature of the experiments. If the experiment is not likely to cause respiratory failure, intubation and mechanical ventilation may not be necessary.

Since respiratory function might be suppressed by anesthesia, endotracheal intubation and mechanical ventilation may be necessary in order to maintain blood gases within the normal range. This is especially relevant during long operations (>1 hour) and when the ischemia affects brain stem function. The components and concentrations of the inspired gas are essential for maintaining arterial blood gases within a normal range when the airway is secured. Oxygen and nitrous oxide are traditionally used in a mixture of 30%:70% (O₂:N₂O) in rodent stroke models. Because nitrous oxide has been shown to be neuroprotective in ischemia-induced brain injury (Abbraini *et al* 2004; Haelewyn *et al* 2008), it may be preferable to use nitrogen mixed with oxygen. Since hyperoxia has been shown to have a neuroprotective effect in brain ischemia (Liu *et al* 2006; Singhal *et al* 2005; Singhal 2007), oxygen concentration and pressure in the inspired air should be controlled at a stable level so as to avoid hypoxia and hyperoxia. Therefore, a mixture of 30%:70% (O₂:N₂) may be used for preclinical stroke trials combined with individual adjustment of ventilator parameters. Note, however, that substituting N₂ for N₂O may slow induction and recovery times, and will generally require that the concentration of volatile anesthetics be adjusted upwards.

Several studies (Bottiger *et al* 1999; Olsson *et al* 2003; Yang *et al* 1997; Yonekura *et al* 2004) have shown that with an inspired gas mixture of 30% O₂ and 70% N₂O, the pre-ischemia levels of partial oxygen pressure (PaO₂), partial carbon dioxide pressure (PaCO₂), and pH varied from 93.4 ± 21.1 to 208 ± 45 mmHg, from 28.1 ± 4.6 to 40 ± 5 mmHg, and from 7.12 ± 0.04 to 7.39 ± 0.08, respectively. One likely reason for these large variations may be that different tidal volume and respiratory rates were used throughout these studies. For example, the respiratory rate and the stroke volume were set at 120 breaths /min and 0.25 ml in the studies of Olsson *et al* (Olsson *et al* 2003) whilst they were set as 130 breaths /min 0.7 ml in those by Sheng *et al* (Sheng *et al* 1999). In addition, the normal resting tidal volume of animals ordinarily will increase, and the respiratory rate will decrease, in proportion to increases in body weight.

B. MONITORING GLUCOSE

GUIDANCE

It is necessary to monitor blood glucose levels before, during and after ischemia, especially in models causing severe brain damage, or in certain newly acquired genetically modified strains. A glucose meter may be preferable to the

integrated glucose measurement function of a standard blood gas analyzer. During the post-surgery stage, hypoglycemia can be prevented by proper care. An animal's appetite, food consumption, and body weight should be monitored, and supplemental administration of glucose by gavage or intraperitoneal injection may be needed. Hyperglycemia can be prevented by fasting the animal overnight before surgery. Any observed hyperglycemia is usually not treated, but it may be used as a criterion for subgrouping or excluding animals in data analyses.

SUPPORTING DISCUSSION

Since hyperglycemia can cause exacerbation of ischemic damage, glucose should be routinely measured during experimental stroke (Lovblad *et al* 2003; Parsons *et al* 2002). Many commonly used volatile anesthetics such as isoflurane and halothane cause a rapid increase in blood glucose (Saha *et al* 2005). Some transgenic animals (Rajkumar *et al* 1995; Rajkumar *et al* 1996) might have congenital diabetes or have a tendency to suffer hyperglycemia after an ischemic insult. In contrast, the loss of appetite or inability to access food may also cause hypoglycemia in animals and may potentially affect survival rates and outcomes, especially in small rodents (mice and gerbils).

For blood glucose assay, a glucose meter may give more precise readings than the integrated glucose measurement function incorporated into a blood gas analyser. In addition, a glucose meter uses much less blood than a blood gas analyser and is usually quicker.

C. BLOOD SAMPLING FOR BLOOD GAS ANALYSES

GUIDANCE

Blood sampling is necessary for periodic measurement of arterial blood gas and frequency of measurement should be selected with reference to animal size. Although pulse oximetry for measuring oxygen saturation has been widely used in clinics, its value in middle cerebral artery occlusion (MCAO) models is not clear. It may be considered as an alternative option when blood sampling from mice/gerbils is not possible.

SUPPORTING DISCUSSION

In larger animals, it is feasible to adjust the stroke volume and the respiratory rate of the ventilator based on the periodic measurement of arterial blood gas. However, frequent blood sampling is not possible in small animals like gerbils and mice, due to their limited blood volume. In our experience, two blood samples (0.08ml per time) can be taken in mice using a capillary tube without affecting the survival

rate and ischemic outcome. The first sample could be taken 10 minutes after ventilation and before ischemia; the second sample can usually be taken right after ischemia has ended. The first sample is preferably used to determine whether the ventilator is set properly because physiological parameters may change significantly in the post ischemia period (Bottiger *et al* 1999).

12. BLOOD PRESSURE

GUIDANCE

Monitoring blood pressure during experiments is needed because blood pressure fluctuation affects stroke outcomes. Blood pressure can be monitored by non-invasive and invasive methods. Use non-invasive methods for experiments that cause minimal blood pressure fluctuation and require a neurological evaluation. Use invasive methods for experiments that require constant blood pressure monitoring. Blood pressure fluctuation due to cerebral ischemia is usually not corrected during the experiment, although it can be used as a guide to anesthetic depth and the concentration of inspired anesthetic gas can be adjusted if appropriate.

SUPPORTING DISCUSSION

In stroke models blood pressure can fluctuate due to anesthetic depth and changes in animal body temperature. In addition, during the ischemic period, blood pressure may be elevated due to the systemic response in attempting to maintain a normal brain perfusion pressure. The change of blood pressure affects regional cerebral blood flow and hence stroke outcome (Drummond *et al* 2000; Kawaguchi *et al* 2004) and clinical trials (Cole *et al* 1990; Rordorf *et al* 1997; Wise 1970; Zhu and Auer 1995). Therefore, blood pressure should be monitored during experiments, especially when a significant fluctuation of blood pressure is expected.

Non-invasive blood pressure monitors are equipped with tail-cuff devices for artery occlusion and oscillometric pulse detectors for readings. Because of the limited accuracy and the relatively long interval (in minutes) between two sequential measurements, this method is not suitable for experiments that need constant blood pressure monitoring.

Invasive blood pressure monitoring provides constant readings throughout the experiment. A disadvantage of invasive blood pressure monitoring, however, is the need to establish an arterial line to connect to a pressure transducer. Additionally, when cannulation of the femoral artery is utilized, the cannulating process and the wound associated with the arterial line may interfere with subsequent neurological function evaluation because of pain, impaired blood

flow and potential nerve injury in the affected limb (Zlotnik *et al* 2008). However, if the arterial line used for blood sampling is also used for blood pressure monitoring the problems are minimized.

Blood pressure is a sensitive indicator for assessing anesthetic depth, and is also an indicator for ventilation efficiency. Anesthetic dose and ventilation can be modified accordingly before the systemic blood gas changes occur. With the exception of experiments specifically designed for studying the effects of blood pressure on brain injury, blood pressure manipulation is usually not suggested when the blood pressure fluctuation is a result of an ischemic insult. In addition, the blood pressure information obtained during experiments may serve as evidence for exclusion or inclusion of animals for the final analyses.

13. THE IMPORTANCE OF A PILOT STUDY

GUIDANCE

A pilot study should be performed before the implementation of a preclinical stroke trial. Stroke model success rate, mortality rate, outcome variation, and sample size should be determined through the pilot study.

SUPPORTING DISCUSSION

Although information regarding the suture size, coating length, insertion length, and related surgical procedures is available in the literature, these parameters may not be optimal for your own experiment. In addition, the intraluminal stroke model demands delicate surgical skill; inexperienced surgeons need a period of time to command the necessary skills for producing acceptably consistent results, which is referred to as the “surgeon’s learning curve” (Renzulli and Laffer 2005). For these modeling reasons, a pilot study is needed to find out the optimal parameters for the MCAO suture and the lab settings for any new study. The pilot study will also be helpful for study design because it may provide the closest information for the expected infarct variation, success rate, and mortality rate.

14. IMPLEMENTATION OF THE PRECLINICAL STROKE TRIAL

A. ADHERE TO “GOOD LABORATORY PRACTICE”

The implementation of a preclinical stroke trial should be conducted with high standards so that experimental bias can be minimized. Some journals have set “Good Laboratory Practice” standards for publishing preclinical trials, and

only studies fulfilling these standards will be accepted for publication in these journals. As stated in “Good Laboratory Practice” (Macleod *et al* 2009a; Macleod *et al* 2009b; Macleod *et al* 2009c), a preclinical stroke trial should be conducted with a clear methodology which includes at least the following items,:

- Detailed information on animals used;
- Sample Size Calculation;
- Inclusion and Exclusion Criteria;
- Randomization;
- Allocation Concealment;
- Reporting of Animals Excluded From Analysis;
- Blinded Assessment of Outcome;
- Reporting Potential Conflicts of Interest and Study Funding.

B. USE APPROPRIATE STATISTICAL METHODS FOR DATA ANALYSES

It is very important to use the correct statistical method for data analyses. Scaled data (such as neurological evaluation and semi-quantitative data) and categorical data (such as mortality rates) should be treated with caution because incorrect statistical methods may lead to invalid conclusions. As discussed in the *Functional Evaluation* section, scaled neurological scores may not always conform to a normal distribution and non-parametric statistical analyses should be used if the data can't pass a normality test. For example, one should use a *Mann-Whitney U*-test (Estevez and Phillis 1997) for two group comparison and a *Kruskal-Wallis* analysis of ranks (Meden *et al* 2002; Onal *et al* 1997) for multiple group comparison. The mortality rate is a type of categorical data; therefore, its analysis should use the *Chi-Square* test (Lu *et al* 2009), not *Student's t*-test (Tang *et al* 2005).

15. FACTORS BEYOND SCIENCE

A. THE NEED FOR SOPS FOR STROKE MODELS

Stroke model procedures, especially those steps that influence model quality, have not yet been standardized. Investigators in each laboratory implement the stroke model with their own lab-settings. In addition, many models have been conducted using suboptimal procedures. This situation makes the results less comparable between laboratories. Standard operational procedures (SOP) for stroke models, if available, may help to improve inter-lab comparability and reduce outcome variations. Relevant organizations, such as the Society for Experimental Stroke (SFES), National Institutes of Health (NIH), National Stroke Association, American Stroke Association, and International Society for Cerebral Blood Flow and Metabolism (ISCBFM) may take a

leadership role in promoting development of an SOP for stroke models.

B. TECHNICAL CHALLENGES IN STROKE MODELS

Some variations in stroke model outcomes are due to technical difficulties in stroke model procedures. The following technical challenges comprise a wishlist for the improvement of stroke model quality:

- Non-invasive blood pressure monitor with constant reading.
- Minimally invasive remote brain temperature monitoring.
- Warm chamber equipped with PID temperature controller and in vivo feedback.
- Remote/in vivo blood gas analyser, glucose monitor.
- Light weight microclips for MCAO.
- Micromanipulator for applying microclips, bipolar coagulator on MCA.
- Uniformly shaped and lysing-controllable emboli for embolic MCAO model.
- Optimized surgical tools for MCAO models.
- Method for in vivo detection of cerebral arterial structure variation.

ACKNOWLEDGEMENT

This work was supported by NIH grants 5T32NS051147-02 and NS-21076-24. The authors appreciate and acknowledge Dr. Levine at Mount Sinai School of Medicine for his contribution on revising this paper.

REFERENCES

- Abraimi JH, David HN, Nicole O, MacKenzie ET, Buisson A, Le-maire M. (2004) Neuroprotection by nitrous oxide and xenon and its relation to minimum alveolar concentration. *Anesthesiology* 101:260-261; author reply 261
- Bayona NA, Gelb AW, Jiang Z, Wilson JX, Urquhart BL, Cechetto DF. (2004) Propofol neuroprotection in cerebral ischemia and its effects on low-molecular-weight antioxidants and skilled motor tasks. *Anesthesiology* 100:1151-1159
- Becker K, Kindrick D, Relton J, Harlan J, Winn R. (2001) Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. *Stroke* 32:206-211
- Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bartkowski HM. (1986a) Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. *Stroke* 17:1304-1308
- Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. (1986b) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. *Stroke* 17:472-476
- Beech JS, Williams SC, Campbell CA, Bath PM, Parsons AA, Hunter AJ, Menon DK. (2001) Further characterisation of a thromboembolic model of stroke in the rat. *Brain Res* 895:18-24

- Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. (1996) Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. *Stroke* 27:1616-1622; discussion 1623
- Belayev L, Busto R, Zhao W, Fernandez G, Ginsberg MD. (1999) Middle cerebral artery occlusion in the mouse by intraluminal suture coated with poly-L-lysine: neurological and histological validation. *Brain Res* 833:181-190
- Benedek A, Moricz K, Juranyi Z, Gigler G, Levay G, Harsing LG, Jr., Matyus P, Szenasi G, Albert M. (2006) Use of TTC staining for the evaluation of tissue injury in the early phases of reperfusion after focal cerebral ischemia in rats. *Brain Res* 1116:159-165
- Biernaskie J, Corbett D, Peeling J, Wells J, Lei H. (2001) A serial MR study of cerebral blood flow changes and lesion development following endothelin-1-induced ischemia in rats. *Magn Reson Med* 46:827-830
- Bostek CC. (1989) Oxygen toxicity: an introduction. *AANA J* 57:231-237
- Bottiger BW, Teschendorf P, Krumnikl JJ, Vogel P, Galmbacher R, Schmitz B, Motsch J, Martin E, Gass P. (1999) Global cerebral ischemia due to cardiocirculatory arrest in mice causes neuronal degeneration and early induction of transcription factor genes in the hippocampus. *Brain Res Mol Brain Res* 65:135-142
- Brint S, Jacewicz M, Kiessling M, Tanabe J, Pulsinelli W. (1988) Focal brain ischemia in the rat: methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral and ipsilateral common carotid arteries. *J Cereb Blood Flow Metab* 8:474-485
- Buchan AM, Xue D, Slivka A. (1992) A new model of temporary focal neocortical ischemia in the rat. *Stroke* 23:273-279
- Buchhold B, Mogoanta L, Suofu Y, Hamm A, Walker L, Kessler C, Popa-Wagner A. (2007) Environmental enrichment improves functional and neuropathological indices following stroke in young and aged rats. *Restor Neurol Neurosci* 25:467-484
- Bulte DP, Chiarelli PA, Wise RG, Jezzard P. (2007) Cerebral perfusion response to hyperoxia. *J Cereb Blood Flow Metab* 27:69-75
- Busch E, Kruger K, Hossmann KA. (1997) Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat. *Brain Res* 778:16-24
- Candelario-Jalil E, Munoz E, Fiebich BL. (2008) Detrimental effects of tropisetron on permanent ischemic stroke in the rat. *BMC Neurosci* 9:19
- Chang S, Jiang X, Zhao C, Lee C, Ferriero DM. (2008) Exogenous low dose hydrogen peroxide increases hypoxia-inducible factor-1 α protein expression and induces preconditioning protection against ischemia in primary cortical neurons. *Neurosci Lett* 441:134-138
- Chen F, Suzuki Y, Nagai N, Peeters R, Sun X, Coudyzer W, Marchal G, Ni Y. (2004) Rat cerebral ischemia induced with photochemical occlusion of proximal middle cerebral artery: a stroke model for MR imaging research. *MAGMA* 17:103-108
- Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, Chopp M. (2001) Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. *Stroke* 32:1005-1011
- Chen ST, Hsu CY, Hogan EL, Maricq H, Balentine JD. (1986) A model of focal ischemic stroke in the rat: reproducible extensive cortical infarction. *Stroke* 17:738-743
- Chen Y, Ito A, Takai K, Saito N. (2008) Blocking pterygopalatine arterial blood flow decreases infarct volume variability in a mouse model of intraluminal suture middle cerebral artery occlusion. *J Neurosci Methods* 174:18-24
- Cho S, Szeto HH, Kim E, Kim H, Tolhurst AT, Pinto JT. (2007) A novel cell-permeable antioxidant peptide, SS31, attenuates ischemic brain injury by down-regulating CD36. *J Biol Chem* 282:4634-4642
- Coert BA, Anderson RE, Meyer FB. (1999) Reproducibility of cerebral cortical infarction in the wistar rat after middle cerebral artery occlusion. *J Stroke Cerebrovasc Dis* 8:380-387
- Coert BA, Anderson RE, Meyer FB. (2003) Is neuroprotective efficacy of nNOS inhibitor 7-NI dependent on ischemic intracellular pH? *Am J Physiol Heart Circ Physiol* 284:H151-159
- Colbourne F, Corbett D, Zhao Z, Yang J, Buchan AM. (2000) Prolonged but delayed postischemic hypothermia: a long-term outcome study in the rat middle cerebral artery occlusion model. *J Cereb Blood Flow Metab* 20:1702-1708
- Cole DJ, Drummond JC, Shapiro HM, Zornow MH. (1990) Influence of hypotension and hypotensive technique on the area of profound reduction in cerebral blood flow during focal cerebral ischaemia in the rat. *Br J Anaesth* 64:498-502
- Czurko A, Nishino H. (1993) 'Collapsed' (argyrophilic, dark) neurons in rat model of transient focal cerebral ischemia. *Neurosci Lett* 162:71-74
- David CA, Prado R, Dietrich WD. (1996) Cerebral protection by intermittent reperfusion during temporary focal ischemia in the rat. *J Neurosurg* 85:923-928
- David HN, Haelewyn B, Rouillon C, Lecoq M, Chazalviel L, Apiou G, Risso JJ, Lemaire M, Abraini JH. (2008) Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. *Faseb J* 22:1275-1286
- De Ryck M, Keersmaekers R, Duytschaever H, Claes C, Clincke G, Janssen M, Van Reet G. (1996) Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. *J Pharmacol Exp Ther* 279:748-758
- De Ryck M, Van Reempts J, Borgers M, Wauquier A, Janssen PA. (1989) Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. *Stroke* 20:1383-1390
- De Ryck M, Verhoye M, Van der Linden AM. (2000) Diffusion-weighted MRI of infarct growth in a rat photochemical stroke model: effect of lubeluzole. *Neuropharmacology* 39:691-702
- DeBow S, Colbourne F. (2003) Brain temperature measurement and regulation in awake and freely moving rodents. *Methods* 30:167-171
- Dettmers C, Hartmann A, Rommel T, Kramer S, Pappata S, Young A, Hartmann S, Zierz S, MacKenzie ET, Baron JC. (1994) Immersion and perfusion staining with 2,3,5-triphenyltetrazolium chloride (TTC) compared to mitochondrial enzymes 6 hours after MCA-occlusion in primates. *Neurol Res* 16:205-208
- Dimitrijevic OB, Stamatovic SM, Keep RF, Andjelkovic AV. (2007) Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. *Stroke* 38:1345-1353
- Diringer MN. (2008) Hyperoxia: good or bad for the injured brain? *Curr Opin Crit Care* 14:167-171
- Dirnagl U. (2006) Bench to bedside: the quest for quality in experimental stroke research. *J Cereb Blood Flow Metab* 26:1465-1478
- Dittmar MS, Vatankhah B, Fehm NP, Schuierer G, Bogdahn U, Horn M, Schlachetzki F. (2006) Fischer-344 rats are unsuitable for the MCAO filament model due to their cerebrovascular anatomy. *J Neurosci Methods* 156:50-54
- Drummond DC, Zignani M, Leroux J. (2000) Current status of pH-sensitive liposomes in drug delivery. *Prog Lipid Res* 39:409-460
- Drummond JC, Cole DJ, Patel PM, Reynolds LW. (1995) Focal cerebral ischemia during anesthesia with etomidate, isoflurane, or thiopental: a comparison of the extent of cerebral injury. *Neurosurgery* 37:742-748; discussion 748-749
- Eichenbaum JW, Pevsner PH, Pivawer G, Kleinman GM, Chiriboga L, Stern A, Rosenbach A, Iannuzzi K, Miller DC. (2002) A murine photochemical stroke model with histologic correlates of apoptotic and nonapoptotic mechanisms. *J Pharmacol Toxicol Methods* 47:67-71

- Erdem AF, Cesur M, Alici HA, Erdogan F, Dogan N, Kursad H, Yuksek MS. (2005) Effects of sevoflurane and desflurane in CA1 after incomplete cerebral ischemia in rats. *Saudi Med J* 26:1424-1428
- Erdo F, Berzsenyi P, Nemet L, Andrasi F. (2006) Talampanel improves the functional deficit after transient focal cerebral ischemia in rats. A 30-day follow up study. *Brain Res Bull* 68:269-276
- Estevez AY, Phillis JW. (1997) The phospholipase A2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion. *Brain Res* 752:203-208
- Fisher M. (2003) Recommendations for Advancing Development of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable 3. *Stroke* 34:1539-1546
- Fisher M, (Stroke Therapy Academic Industry Roundtable, I. V.). (2005) Enhancing the Development and Approval of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable. *Stroke* 36:1808-1813
- Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH. (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. *Stroke* 40:2244-2250
- Fisher M, Hanley DF, Howard G, Jauch EC, Warach S, for the SG. (2007) Recommendations From the STAIR V Meeting on Acute Stroke Trials, Technology and Outcomes. *Stroke* 38:245-248
- Florian B, Vintilescu R, Balseanu AT, Buga AM, Grisk O, Walker LC, Kessler C, Popa-Wagner A. (2008) Long-term hypothermia reduces infarct volume in aged rats after focal ischemia. *Neurosci Lett* 438:180-185
- Futrell N, Watson BD, Dietrich WD, Prado R, Millikan C, Ginsberg MD. (1988) A new model of embolic stroke produced by photochemical injury to the carotid artery in the rat. *Ann Neurol* 23:251-257
- Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J, Chen S, Chopp M. (1993) Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. *Am J Pathol* 142:623-635
- Gaudinski MR, Henning EC, Miracle A, Luby M, Warach S, Latour LL. (2008) Establishing final infarct volume: stroke lesion evolution past 30 days is insignificant. *Stroke* 39:2765-2768
- Goldlust EJ, Paczynski RP, He YY, Hsu CY, Goldberg MP. (1996) Automated measurement of infarct size with scanned images of triphenyltetrazolium chloride-stained rat brains. *Stroke* 27:1657-1662
- Grasshoff C, Rudolph U, Antkowiak B. (2005) Molecular and systemic mechanisms of general anaesthesia: the 'multi-site and multiple mechanisms' concept. *Curr Opin Anaesthesiol* 18:386-391
- Greco R, Amantea D, Blandini F, Nappi G, Bagetta G, Corasaniti MT, Tassorelli C. (2007) Neuroprotective effect of nitroglycerin in a rodent model of ischemic stroke: evaluation of Bcl-2 expression. *Int Rev Neurobiol* 82:423-435
- Greene SA, Thurmon JC, Tranquilli WJ, Benson GJ. (1987) Effect of yohimbine on xylazine-induced hypoinsulinemia and hyperglycemia in mares. *Am J Vet Res* 48:676-678
- Haelewyn B, David HN, Rouillon C, Chazalviel L, Lecocq M, Rizzo JJ, Lemaire M, Abraini JH. (2008) Neuroprotection by nitrous oxide: facts and evidence. *Crit Care Med* 36:2651-2659
- Haelewyn B, Yvon A, Hanouz JL, MacKenzie ET, Ducouret P, Gerard JL, Roussel S. (2003) Desflurane affords greater protection than halothane against focal cerebral ischaemia in the rat. *Br J Anaesth* 91:390-396
- Harada T, Kano T, Katayama Y, Matsuzaki T, Teijima E, Koshinaga M. (2005) Tissue plasminogen activator extravasated through the cerebral vessels: evaluation using a rat thromboembolic stroke model. *Thromb Haemostasis* 94:791-796
- Horie N, Maag AL, Hamilton SA, Shichinohe H, Bliss TM, Steinberg GK. (2008) Mouse model of focal cerebral ischemia using endothelin-1. *J Neurosci Methods* 173:286-290
- Horita Y, Honmou O, Harada K, Houkin K, Hamada H, Kocsis JD. (2006) Intravenous administration of glial cell line-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat. *J Neurosci Res* 84:1495-1504
- Huang J, Kim LJ, Poisk A, Pinsky DJ, Connolly ES, Jr. (1998) Does poly-L-lysine coating of the middle cerebral artery occlusion suture improve infarct consistency in a murine model? *J Stroke Cerebrovasc Dis* 7:296-301
- Hungerhuber E, Zausinger S, Westermaier T, Plesnila N, Schmid-Elsaesser R. (2006) Simultaneous bilateral laser Doppler fluxmetry and electrophysiological recording during middle cerebral artery occlusion in rats. *J Neurosci Methods* 154:109-115
- Isayama K, Pitts LH, Nishimura MC. (1991) Evaluation of 2,3,5-triphenyltetrazolium chloride staining to delineate rat brain infarcts. *Stroke* 22:1394-1398
- Iwatsuki N, Takahashi M, Ono K, Tajima T. (1994) Hyperbaric oxygen combined with nicardipine administration accelerates neurologic recovery after cerebral ischemia in a canine model. *Crit Care Med* 22:858-863
- Jia X, Koenig MA, Shin HC, Zhen G, Yamashita S, Thakor NV, Geocadin RG. (2006) Quantitative EEG and neurological recovery with therapeutic hypothermia after asphyxial cardiac arrest in rats. *Brain Res* 1111:166-175
- Joshi CN, Jain SK, Murthy PS. (2004) An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts. *Brain Res Brain Res Protoc* 13:11-17
- Kano T, Harada T, Katayama Y. (2003) Infiltration of tissue plasminogen activator through cerebral vessels: evaluation using a rat thromboembolic stroke model. *Acta Neurochir Suppl* 86:167-168
- Kano T, Harada T, Katayama Y. (2005) Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model. *Neurol Res* 27:499-502
- Kawaguchi M, Drummond JC, Cole DJ, Kelly PJ, Spurlock MP, Patel PM. (2004) Effect of isoflurane on neuronal apoptosis in rats subjected to focal cerebral ischemia. *Anesth Analg* 98:798-805, table of contents
- Khan M, Jatana M, Elango C, Paintlia AS, Singh AK, Singh I. (2006) Cerebrovascular protection by various nitric oxide donors in rats after experimental stroke. *Nitric Oxide* 15:114-124
- Kilic E, Hermann DM, Hossmann KA. (1998) A reproducible model of thromboembolic stroke in mice. *Neuroreport* 9:2967-2970
- Kim E, Tolhurst AT, Qin LY, Chen XY, Febbraio M, Cho S. (2008) CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury. *J Neurosci* 28:4661-4670
- Kim Y, Busto R, Dietrich WD, Kraydieh S, Ginsberg MD. (1996) Delayed postischemic hyperthermia in awake rats worsens the histopathological outcome of transient focal cerebral ischemia. *Stroke* 27:2274-2280; discussion 2281
- Kitagawa K, Matsumoto M, Hori M. (2004) Cerebral ischemia in 5-lipoxygenase knockout mice. *Brain Res* 1004:198-202
- Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. (2007) Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. *Circulation* 115:2323-2330
- Koizumi J, Yoshida Y, Nakazawa T, Ooneda G. (1986) Experimental studies of ischemic brain edema, I: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. *Jpn J Stroke* 8:1-8
- Kontos HA, Raper AJ, Patterson JL. (1977a) Analysis of vasoactivity of local pH, PCO2 and bicarbonate on pial vessels. *Stroke* 8:358-360
- Kontos HA, Wei EP, Raper AJ, Patterson JL, Jr. (1977b) Local mechanism of CO2 action of cat pial arterioles. *Stroke* 8:226-229

- Krueger K, Busch E. (2002) Protocol of a thromboembolic stroke model in the rat: review of the experimental procedure and comparison of models. *Invest Radiol* 37:600-608
- Kudo M, Aoyama A, Ichimori S, Fukunaga N. (1982) An animal model of cerebral infarction. Homologous blood clot emboli in rats. *Stroke* 13:505-508
- Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs M. (1993) BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. *Stroke* 24:1063-1067
- Lee JK, Kim JE, Sivula M, Strittmatter SM. (2004) Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. *J Neurosci* 24:6209-6217
- Lin TN, He YY, Wu G, Khan M, Hsu CY. (1993) Effect of brain edema on infarct volume in a focal cerebral ischemia model in rats. *Stroke* 24:117-121
- Lindner MD, Gribkoff VK, Donlan NA, Jones TA. (2003) Long-lasting functional disabilities in middle-aged rats with small cerebral infarcts. *J Neurosci* 23:10913-10922
- Liszczyk TM, Hedley-Whyte ET, Adams JF, Han DH, Kolluri VS, Vacanti FX, Heros RC, Zervas NT. (1984) Limitations of tetrastazolium salts in delineating infarcted brain. *Acta Neuropathol* 65:150-157
- Liu S, Guo Y. (2000a) [Dynamic penumbra in a rat model of focal cerebral ischemia and reperfusion]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 22:177-181
- Liu S, Guo Y. (2000b) [Identification of early irreversible damage area in a rat model of cerebral ischemia and reperfusion]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 22:25-29
- Liu S, Levine SR. (2008) The continued promise of neuroprotection for acute stroke treatment. *J Exp Stroke & Transl Med* 1:1-8
- Liu S, Liu W, Ding W, Miyake M, Rosenberg GA, Liu KJ. (2006) Electron paramagnetic resonance-guided normobaric hyperoxia treatment protects the brain by maintaining penumbral oxygenation in a rat model of transient focal cerebral ischemia. *J Cereb Blood Flow Metab* 26:1274-1284
- Liu S, Shi H, Liu W, Furuichi T, Timmins GS, Liu KJ. (2004) Interstitial pO₂ in ischemic penumbra and core are differentially affected following transient focal cerebral ischemia in rats. *J Cereb Blood Flow Metab* 24:343-349
- Longa EZ, Weinstein PR, Carlson S, Cummins R. (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. *Stroke* 20:84-91
- Lovblad KO, El-Koussy M, Oswald H, Baird AE, Schroth G, Mattle H. (2003) Magnetic resonance imaging of the ischaemic penumbra. *Swiss Med Wkly* 133:551-559
- Lozano JD, Abulafia DP, Danton GH, Watson BD, Dietrich WD. (2007) Characterization of a thromboembolic photochemical model of repeated stroke in mice. *J Neurosci Methods* 162:244-254
- Lu A, Kurosawa Y, Luskey K, Pyne-Geithman G, Caudell D, Clark J. (2009) Hemorrhagic profile of the fibrinolytic alteplase after ischemia and reperfusion. *Neurol Res* 31:209-214
- Lundy EF, Solik BS, Frank RS, Lacy PS, Combs DJ, Zelenock GB, D'Alecy LG. (1986) Morphometric evaluation of brain infarcts in rats and gerbils. *J Pharmacol Methods* 16:201-214
- Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, van der Worp HB, Traystman R, Minematsu K, Donnan GA, Howells DW. (2009a) Good laboratory practice: preventing introduction of bias at the bench. *Stroke* 40:e50-52
- Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, van der Worp HB, Traystman RJ, Minematsu K, Donnan GA, Howells DW. (2009b) Reprint: Good laboratory practice: preventing introduction of bias at the bench. *Int J Stroke* 4:3-5
- Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, Buchan A, van der Worp HB, Traystman RJ, Minematsu K, Donnan GA, Howells DW. (2009c) Reprint: Good laboratory practice: preventing introduction of bias at the bench. *J Cereb Blood Flow Metab* 29:221-223
- Maggi CA, Meli A. (1986) Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 1: General considerations. *Experientia* 42:109-114
- Margail I, Parmentier S, Callebort J, Allix M, Boulu RG, Plotkine M. (1996) Short therapeutic window for MK-801 in transient focal cerebral ischemia in normotensive rats. *J Cereb Blood Flow Metab* 16:107-113
- Marion DW. (2004) Controlled normothermia in neurologic intensive care. *Crit Care Med* 32:S43-45
- Masada T, Hua Y, Xi G, Ennis SR, Keep RF. (2001) Attenuation of ischemic brain edema and cerebrovascular injury after ischemic preconditioning in the rat. *J Cereb Blood Flow Metab* 21:22-33
- Matsushima K, Hakim AM. (1995) Transient forebrain ischemia protects against subsequent focal cerebral ischemia without changing cerebral perfusion. *Stroke* 26:1047-1052
- Maysami S, Lan JQ, Minami M, Simon RP. (2008) Proliferating progenitor cells: a required cellular element for induction of ischemic tolerance in the brain. *J Cereb Blood Flow Metab* 28:1104-1113
- McIlvoy L. (2004) Comparison of brain temperature to core temperature: a review of the literature. *J Neurosci Nurs* 36:23-31
- Meden P, Andersen M, Overgaard K, Rasmussen RS, Boysen G. (2002) The effects of early insulin treatment combined with thrombolysis in rat embolic stroke. *Neurol Res* 24:399-404
- Menzel M, Rieger A, Roth S, Soukup J, Furka I, Miko I, Molnar P, Peuse C, Hennig C, Radke J. (1998) Comparison between continuous brain tissue pO₂, pCO₂, pH, and temperature and simultaneous cerebrovenous measurement using a multisensor probe in a porcine intracranial pressure model. *J Neurotrauma* 15:265-276
- Miyazawa T, Tamura A, Fukui S, Hossmann KA. (2003) Effect of mild hypothermia on focal cerebral ischemia. Review of experimental studies. *Neurol Res* 25:457-464
- Morikawa E, Ginsberg MD, Dietrich WD, Duncan RC, Kraydieh S, Globus MY, Busto R. (1992) The significance of brain temperature in focal cerebral ischemia: histopathological consequences of middle cerebral artery occlusion in the rat. *J Cereb Blood Flow Metab* 12:380-389
- Nakajima Y, Moriwaki G, Ikeda K, Fujise Y. (1997) The effects of sevoflurane on recovery of brain energy metabolism after cerebral ischemia in the rat: a comparison with isoflurane and halothane. *Anesth Analg* 85:593-599
- Nikolova S, Moyanova S, Hughes S, Bellyou-Camilleri M, Lee TY, Bartha R. (2009) Endothelin-1 induced MCAO: dose dependency of cerebral blood flow. *J Neurosci Methods* 179:22-28
- Noor R, Wang CX, Shuaib A. (2003) Effects of hyperthermia on infarct volume in focal embolic model of cerebral ischemia in rats. *Neurosci Lett* 349:130-132
- Noor R, Wang CX, Shuaib A. (2005) Hyperthermia masks the neuroprotective effects of tissue plasminogen activator. *Stroke* 36:665-669
- Nussmeier NA. (2005) Management of temperature during and after cardiac surgery. *Tex Heart Inst J* 32:472-476
- Ohta H, Terao Y, Shintani Y, Kiyota Y. (2007) Therapeutic time window of post-ischemic mild hypothermia and the gene expression associated with the neuroprotection in rat focal cerebral ischemia. *Neurosci Res* 57:424-433
- Oliff HS, Weber E, Eilon G, Marek P. (1995a) The role of strain/vendor differences on the outcome of focal ischemia induced by intraluminal middle cerebral artery occlusion in the rat. *Brain Res* 675:20-26
- Oliff HS, Weber E, Miyazaki B, Marek P. (1995b) Infarct volume varies with rat strain and vendor in focal cerebral ischemia induced by transcranial middle cerebral artery occlusion. *Brain Res* 699:329-331
- Olsson T, Wieloch T, Smith ML. (2003) Brain damage in a mouse model of global cerebral ischemia. Effect of NMDA receptor blockade. *Brain Res* 982:260-269

- Onal MZ, Li F, Tattisumak T, Locke KW, Sandage BW, Jr., Fisher M. (1997) Synergistic effects of citicoline and MK-801 in temporary experimental focal ischemia in rats. *Stroke* 28:1060-1065
- Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E, Agin V, Vivien D. (2007) Mouse model of in situ thromboembolic stroke and reperfusion. *Stroke* 38:2771-2778
- Ostrovskaya RU, Romanova GA, Barskov IV, Shanina EV, Gudashva TA, Victorov IV, Voronina TA, Seredenin SB. (1999) Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model. *Behav Pharmacol* 10:549-553
- Overgaard K, Meden P. (2000) Influence of different fixation procedures on the quantification of infarction and oedema in a rat model of stroke. *Neuropathol Appl Neurobiol* 26:243-250
- Parsons MW, Barber PA, Desmond PM, Baird TA, Darby DG, Byrnes G, Tress BM, Davis SM. (2002) Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. *Ann Neurol* 52:20-28
- Payne RS, Akca O, Roewer N, Schurr A, Kehl F. (2005) Sevoflurane-induced preconditioning protects against cerebral ischemic neuronal damage in rats. *Brain Res* 1034:147-152
- Pettigrew LC, Holtz ML, Craddock SD, Minger SL, Hall N, Geddes JW. (1996) Microtubular proteolysis in focal cerebral ischemia. *J Cereb Blood Flow Metab* 16:1189-1202
- Pignataro G, Simon RP, Boison D. (2007a) Transgenic overexpression of adenosine kinase aggravates cell death in ischemia. *J Cereb Blood Flow Metab* 27:1-5
- Pignataro G, Simon RP, Xiong ZG. (2007b) Prolonged activation of ASIC1a and the time window for neuroprotection in cerebral ischaemia. *Brain* 130:151-158
- Pignataro G, Studer FE, Wilz A, Simon RP, Boison D. (2007c) Neuroprotection in ischemic mouse brain induced by stem cell-derived brain implants. *J Cereb Blood Flow Metab* 27:919-927
- Proescholdt M, Heimann A, Kempfski O. (2001) Neuroprotection of S(+) ketamine isomer in global forebrain ischemia. *Brain Res* 904:245-251
- Rajkumar K, Barron D, Lewitt MS, Murphy LJ. (1995) Growth retardation and hyperglycemia in insulin-like growth factor binding protein-1 transgenic mice. *Endocrinology* 136:4029-4034
- Rajkumar K, Dheen ST, Murphy LJ. (1996) Hyperglycemia and impaired glucose tolerance in IGF binding protein-1 transgenic mice. *Am J Physiol* 270:E565-571
- Reglodi D, Tamas A, Lengvari I. (2003) Examination of sensorimotor performance following middle cerebral artery occlusion in rats. *Brain Res Bull* 59:459-466
- Renzulli P, Laffer UT. (2005) Learning curve: the surgeon as a prognostic factor in colorectal cancer surgery. *Recent Results Cancer Res* 165:86-104
- Rogers DC, Campbell CA, Stretton JL, Mackay KB. (1997) Correlation between motor impairment and infarct volume after permanent and transient middle cerebral artery occlusion in the rat. *Stroke* 28:2060-2065; discussion 2066
- Romanos E, Planas AM, Amaro S, Chamorro A. (2007) Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. *J Cereb Blood Flow Metab* 27:14-20
- Roof RL, Schielke GP, Ren X, Hall ED. (2001) A comparison of long-term functional outcome after 2 middle cerebral artery occlusion models in rats. *Stroke* 32:2648-2657
- Rordorf G, Cramer SC, Efid JT, Schwamm LH, Buonanno F, Koroshetz WJ. (1997) Pharmacological elevation of blood pressure in acute stroke. Clinical effects and safety. *Stroke* 28:2133-2138
- Rusyniak DE, Kirk MA, May JD, Kao LW, Brizendine EJ, Welch JL, Cordell WH, Alonso RJ. (2003) Hyperbaric oxygen therapy in acute ischemic stroke: results of the Hyperbaric Oxygen in Acute Ischemic Stroke Trial Pilot Study. *Stroke* 34:571-574
- Saha JK, Xia J, Grondin JM, Engle SK, Jakubowski JA. (2005) Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical models. *Exp Biol Med (Maywood)* 230:777-784
- Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. (2009) Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. *Stroke* 40:2594-2600
- Savitz SI. (2007) A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. *Exp Neurol* 205:20-25
- Sceniak MP, Maciver MB. (2006) Cellular actions of urethane on rat visual cortical neurons in vitro. *J Neurophysiol* 95:3865-3874
- Schallert T. (2006) Behavioral tests for preclinical intervention assessment. *NeuroRx* 3:497-504
- Schielke GP, Kupina NC, Boxer PA, Bigge CF, Welty DF, Iadecola C. (1999) The neuroprotective effect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat. *Stroke* 30:1472-1477
- Schmid-Elsaesser R, Zausinger S, Hungerhuber E, Baethmann A, Reulen HJ. (1998) A critical reevaluation of the intraluminal thread model of focal cerebral ischemia: evidence of inadvertent premature reperfusion and subarachnoid hemorrhage in rats by laser-Doppler flowmetry. *Stroke* 29:2162-2170
- Selman WR, Bhatti SU, Rosenstein CC, Lust WD, Ratcheson RA. (1994) Temporary vessel occlusion in spontaneously hypertensive and normotensive rats. Effect of single and multiple episodes on tissue metabolism and volume of infarction. *J Neurosurg* 80:1085-1090
- Shah ZA, Namiranian K, Klaus J, Kibler K, Dore S. (2006) Use of an optimized transient occlusion of the middle cerebral artery protocol for the mouse stroke model. *J Stroke Cerebrovasc Dis* 15:133-138
- Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. (1999) Characterization of a recovery global cerebral ischemia model in the mouse. *J Neurosci Methods* 88:103-109
- Shimamura N, Matchett G, Tsubokawa T, Ohkuma H, Zhang J. (2006a) Comparison of silicon-coated nylon suture to plain nylon suture in the rat middle cerebral artery occlusion model. *J Neurosci Methods* 156:161-165
- Shimamura N, Matchett G, Yatsushige H, Calvert JW, Ohkuma H, Zhang J. (2006b) Inhibition of integrin alphavbeta3 ameliorates focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. *Stroke* 37:1902-1909
- Simard JM, Yurovsky V, Tsybalyuk N, Melnichenko L, Ivanova S, Gerzanich V. (2009) Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. *Stroke* 40:604-609
- Singhal AB. (2007) A review of oxygen therapy in ischemic stroke. *Neurol Res* 29:173-183
- Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, Buonanno FS, Gonzalez RG, Sorensen AG. (2005) A pilot study of normobaric oxygen therapy in acute ischemic stroke. *Stroke* 36:797-802
- Singhal AB, Wang X, Sumii T, Mori T, Lo EH. (2002) Effects of normobaric hyperoxia in a rat model of focal cerebral ischemia-reperfusion. *J Cereb Blood Flow Metab* 22:861-868
- Siniscalchi A, Zona C, Guatteo E, Mercuri NB, Bernardi G. (1998) An electrophysiological analysis of the protective effects of felbamate, lamotrigine, and lidocaine on the functional recovery in vitro ischemia in rat neocortical slices. *Synapse* 30:371-379
- Solaroglu I, Tsubokawa T, Cahill J, Zhang JH. (2006) Anti-apoptotic effect of granulocyte-colony stimulating factor after focal cerebral ischemia in the rat. *Neuroscience* 143:965-974
- Spratt NJ, Fernandez J, Chen M, Rewell S, Cox S, van Raay L, Hogan L, Howells DW. (2006) Modification of the method of thread manufacture improves stroke induction rate and re-

- duces mortality after thread-occlusion of the middle cerebral artery in young or aged rats. *J Neurosci Methods* 155:285-290
- STAIR Group. (1999) Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development. *Stroke* 30:2752-2758
- STAIR Group. (2001) Recommendations for Clinical Trial Evaluation of Acute Stroke Therapies. *Stroke* 32:1598-1606
- Stewart VC, Land JM, Clark JB, Heales SJ. (1998) Comparison of mitochondrial respiratory chain enzyme activities in rodent astrocytes and neurones and a human astrocytoma cell line. *Neurosci Lett* 247:201-203
- Stroke Therapy Academic Industry Roundtable. (1999) Recommendations for Standards Regarding Preclinical Neuroprotective and Restorative Drug Development. *Stroke* 30:2752-2758
- Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. (1990) A semiautomated method for measuring brain infarct volume. *J Cereb Blood Flow Metab* 10:290-293
- Takahashi M, Iwatsuki N, Ono K, Tajima T, Akama M, Koga Y. (1992) Hyperbaric oxygen therapy accelerates neurologic recovery after 15-minute complete global cerebral ischemia in dogs. *Crit Care Med* 20:1588-1594
- Tamura A, Graham DI, McCulloch J, Teasdale GM. (1981a) Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. *J Cereb Blood Flow Metab* 1:53-60
- Tamura A, Graham DI, McCulloch J, Teasdale GM. (1981b) Focal cerebral ischaemia in the rat: 2. Regional cerebral blood flow determined by [¹⁴C]iodoantipyrine autoradiography following middle cerebral artery occlusion. *J Cereb Blood Flow Metab* 1:61-69
- Tang J, Liu J, Zhou C, Ostanin D, Grisham MB, Neil Granger D, Zhang JH. (2005) Role of NADPH oxidase in the brain injury of intracerebral hemorrhage. *J Neurochem* 94:1342-1350
- Tejima E, Katayama Y, Suzuki Y, Kano T, Lo EH. (2001) Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. *Stroke* 32:1336-1340
- Thurmon JC, Steffey EP, Zinkl JG, Woliner M, Howland D, Jr. (1984) Xylazine causes transient dose-related hyperglycemia and increased urine volumes in mares. *Am J Vet Res* 45:224-227
- Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC. (2002) Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke. *Stroke* 33:578-585
- Tsai SK, Lin SM, Hung WC, Mok MS, Chih CL, Huang SS. (2004) The effect of desflurane on ameliorating cerebral infarction in rats subjected to focal cerebral ischemia-reperfusion injury. *Life Sci* 74:2541-2549
- Tsubokawa T, Jadhav V, Solaroglu I, Shiokawa Y, Konishi Y, Zhang JH. (2007) Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. *Stroke* 38:1057-1062
- Tsubokawa T, Solaroglu I, Yatsushige H, Cahill J, Yata K, Zhang JH. (2006a) Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats. *Stroke* 37:1888-1894
- Tsubokawa T, Yamaguchi-Okada M, Calvert JW, Solaroglu I, Shimamura N, Yata K, Zhang JH. (2006b) Neurovascular and neuronal protection by E64d after focal cerebral ischemia in rats. *J Neurosci Res* 84:832-840
- Tsuchiya D, Hong S, Kayama T, Panter SS, Weinstein PR. (2003) Effect of suture size and carotid clip application upon blood flow and infarct volume after permanent and temporary middle cerebral artery occlusion in mice. *Brain Res* 970:131-139
- Tureyen K, Vemuganti R, Sailor KA, Dempsey RJ. (2004) Infarct volume quantification in mouse focal cerebral ischemia: a comparison of triphenyltetrazolium chloride and cresyl violet staining techniques. *J Neurosci Methods* 139:203-207
- van der Worp HB, de Haan P, Morrema E, Kalkman CJ. (2005) Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. *J Neurol* 252:1108-1114
- Velisek L. (1998) Extracellular acidosis and high levels of carbon dioxide suppress synaptic transmission and prevent the induction of long-term potentiation in the CA1 region of rat hippocampal slices. *Hippocampus* 8:24-32
- Vornov JJ, Thomas AG, Jo D. (1996) Protective effects of extracellular acidosis and blockade of sodium/hydrogen ion exchange during recovery from metabolic inhibition in neuronal tissue culture. *J Neurochem* 67:2379-2389
- Vosko MR, Busch E, Burggraf D, Bultemeier G, Hamann GF. (2003) Microvascular basal lamina damage in thromboembolic stroke in a rat model. *Neurosci Lett* 353:217-220
- Wallsh E, Weinstein GS, Franzone A, Clavel A, Rossi PA, Kreps E. (1986) Inflammation of the coronary arteries in patients with unstable angina. *Tex Heart Inst J* 13:105-108
- Wang CX, Yang T, Shuaib A. (2001) An improved version of embolic model of brain ischemic injury in the rat. *J Neurosci Methods* 109:147-151
- Warner DS, Takaoka S, Wu B, Ludwig PS, Pearlstein RD, Brinkhaus AD, Dexter F. (1996) Electroencephalographic burst suppression is not required to elicit maximal neuroprotection from pentobarbital in a rat model of focal cerebral ischemia. *Anesthesiology* 84:1475-1484
- Weber ML, Taylor CP. (1994) Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials. *Brain Res* 664:167-177
- Wetzel M, Li L, Harms KM, Roitbak T, Ventura PB, Rosenberg GA, Khokha R, Cunningham LA. (2008) Tissue inhibitor of metalloproteinases-3 facilitates Fas-mediated neuronal cell death following mild ischemia. *Cell Death Differ* 15:143-151
- Windle V, Szymanska A, Granter-Button S, White C, Buist R, Peeling J, Corbett D. (2006) An analysis of four different methods of producing focal cerebral ischemia with endothelin-1 in the rat. *Exp Neurol* 201:324-334
- Winn HR, Rubio R, Berne RM. (1981) Brain adenosine concentration during hypoxia in rats. *Am J Physiol* 241:H235-242
- Wise GR. (1970) Vasopressor-drug therapy for complications of cerebral arteriography. *N Engl J Med* 282:610-612
- Woitzik J, Schneider UC, Thome C, Schroeck H, Schilling L. (2006) Comparison of different intravascular thread occlusion models for experimental stroke in rats. *J Neurosci Methods* 151:224-231
- Xi GM, Wang HQ, He GH, Huang CF, Wei GY. (2004) Evaluation of murine models of permanent focal cerebral ischemia. *Chin Med J (Engl)* 117:389-394
- Xiong L, Zheng Y, Wu M, Hou L, Zhu Z, Zhang X, Lu Z. (2003) Preconditioning with isoflurane produces dose-dependent neuroprotection via activation of adenosine triphosphate-regulated potassium channels after focal cerebral ischemia in rats. *Anesth Analg* 96:233-237, table of contents
- Yamamoto S, Tanaka E, Shoji Y, Kudo Y, Inokuchi H, Higashi H. (1997) Factors that reverse the persistent depolarization produced by deprivation of oxygen and glucose in rat hippocampal CA1 neurons in vitro. *J Neurophysiol* 78:903-911
- Yamashita T, Ninomiya M, Hernandez Acosta P, Garcia-Verdugo JM, Sunabori T, Sakaguchi M, Adachi K, Kojima T, Hirota Y, Kawase T, Araki N, Abe K, Okano H, Sawamoto K. (2006) Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum. *J Neurosci* 26:6627-6636
- Yamauchi A, Shuto H, Dohgu S, Nakano Y, Egawa T, Kataoka Y. (2005) Cyclosporin A aggravates electroshock-induced convulsions in mice with a transient middle cerebral artery occlusion. *Cell Mol Neurobiol* 25:923-928

- Yanamoto H, Nagata I, Hashimoto N, Kikuchi H. (1998) Three-vessel occlusion using a micro-clip for the proximal left middle cerebral artery produces a reliable neocortical infarct in rats. *Brain Res Brain Res Protoc* 3:209-220
- Yanamoto H, Nagata I, Niitsu Y, Xue JH, Zhang Z, Kikuchi H. (2003) Evaluation of MCAO stroke models in normotensive rats: standardized neocortical infarction by the 3VO technique. *Exp Neurol* 182:261-274
- Yang G, Kitagawa K, Matsushita K, Mabuchi T, Yagita Y, Yanagihara T, Matsumoto M. (1997) C57BL/6 strain is most susceptible to cerebral ischemia following bilateral common carotid occlusion among seven mouse strains: selective neuronal death in the murine transient forebrain ischemia. *Brain Res* 752:209-218
- Yang Y, Li Q, Miyashita H, Yang T, Shuaib A. (2001) Different dynamic patterns of extracellular glutamate release in rat hippocampus after permanent or 30-min transient cerebral ischemia and histological correlation. *Neuropathology* 21:181-187
- Yin D, Zhang JH. (2005) Delayed and multiple hyperbaric oxygen treatments expand therapeutic window in rat focal cerebral ischemic model. *Neurocrit Care* 2:206-211
- Yonekura I, Kawahara N, Nakatomi H, Furuya K, Kirino T. (2004) A model of global cerebral ischemia in C57 BL/6 mice. *J Cereb Blood Flow Metab* 24:151-158
- Zaremba J. (2004) Hyperthermia in ischemic stroke. *Med Sci Monit* 10:RA148-153
- Zarow GJ, Karibe H, States BA, Graham SH, Weinstein PR. (1997) Endovascular suture occlusion of the middle cerebral artery in rats: effect of suture insertion distance on cerebral blood flow, infarct distribution and infarct volume. *Neurol Res* 19:409-416
- Zausinger S, Hungerhuber E, Baethmann A, Reulen H, Schmid-Elsaesser R. (2000) Neurological impairment in rats after transient middle cerebral artery occlusion: a comparative study under various treatment paradigms. *Brain Res* 863:94-105
- Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. (1997a) A rat model of focal embolic cerebral ischemia. *Brain Res* 766:83-92
- Zhang Z, Zhang RL, Jiang Q, Raman SB, Cantwell L, Chopp M. (1997b) A new rat model of thrombotic focal cerebral ischemia. *J Cereb Blood Flow Metab* 17:123-135
- Zhu CZ, Auer RN. (1995) Graded hypotension and MCA occlusion duration: effect in transient focal ischemia. *J Cereb Blood Flow Metab* 15:980-988
- Zlotnik A, Gruenbaum SE, Artru AA, Leibovitz A, Shapira Y. (2008) The Position of Arterial Line Significantly Influences Neurological Assessment in Rats. *ASA Annual Meeting Abstract* 109:A486